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Albumin nanoparticles are attractive candidates for optimising drug delivery to the lungs 
by modifying local biodistribution.  However, there has been little exploration of the 
loading of therapeutic agents into albumin-based nanoformulations for inhaled delivery. 
The aim of this work was to develop respirable microparticles containing albumin 
nanoparticles for drug delivery to the lungs. Human serum albumin (HSA) nanoparticle 
suspensions were developed using a modified desolvation method.  The solubility of four 
anti-tuberculosis benzothiazinone (BTZ) drug candidates (IR 20, IF 274, FG 2, AR 112; 
0.38-134 μg/mL) was enhanced 2 to 140-fold by 50 mg/mL (1 mL) albumin. Tryptophan 
213 residue quenching studies indicated moderate drug binding strength to Sudlow’s site 
I.  Nanoparticle manufacture was optimised to provide 37-60% drug encapsulation 
efficiency in HSA particles (169 nm, zeta potential –31 mV).  Drug release was <8% over 
48 h in aqueous medium, but 66-88% was released by 48 h after the addition of proteases 
at concentrations representative of the enzyme levels found in lung lining fluid.  
Dissolution profiles reflected Logistic release kinetics for IR 20 and Weibull release 
kinetics for FG 2 (R2= 0.988 and 0.975, respectively) and antimycobacterial activity in an 
M. tuberculosis infected macrophage model was enhanced compared to delivery in DMSO 
or albumin solution. Pilot spray-drying studies demonstrated that incorporation of 
albumin nanoparticles into respirable carrier particles was possible. The spray-dried 
powders developed in this work were suitably sized for lung deposition (~4 µm) and 
albumin nanoparticles were recoverable after the spray-drying process with good re-
dispersibility and size uniformity. An albumin nanoparticle content in the spray-dried 
mannitol formulation of 40% was selected as the most promising.  HSA nanoparticles 
containing roflumilast, a selective phosphodiesterase 4 inhibitor, were incorporated in the 
dry powder formulation with little effect on the aerodynamic properties of the powders 
produced. Roflumilast release from the spray-dried microcarriers was found to be the 
same as from the suspension form (<20% at 48 hours without the presence of trypsin, and 
a rapid release rate for the first 4 hours with the presence of trypsin, followed by a slower 
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rate for the remaining 48 hours (total ~80% drug release). Dose deposition in human 
lungs was modelled using the PreciseInhale® system, indicating that aerosol 
administration of a single capsule containing 10 mg of the dry powder formulation would 
deliver roughly 6 µg roflumilast. This work demonstrates opportunities for developing 
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1.1 General introduction 
The overall aim of this thesis was to develop a respirable microparticle formulation 
containing drug-loaded albumin nanoparticles for delivery to the lungs. In this chapter, 
important background to the topic of aerosolised medicine delivery to the lungs will be 
discussed, including inhaled nanoparticle delivery and aerosol formulation. This chapter 
will also provide an introduction to albumin; namely its structure, drug-binding 
properties, nanoparticle formation and the biological fate of albumin nanoparticles, i.e. 
their retention and degradation in the lungs. Finally, the specific objectives addressed in 
this thesis are defined. 
 
1.2 Nanoparticle-based aerosol medicine 
The definition of nanoparticle most commonly specifies particles in the size range 1 – 
1000 nm, however in terms of drug delivery the size range 1 – 200 nm is usually inferred 
(Kreuter 1991). Nanoparticles have been recognised as having potential for providing 
controlled drug delivery to the lung for some years (Paranjpe & Müller-Goymann 2014). 
Their versatility and ability to address some of the problems encountered in inhaled drug 
delivery, e.g. loss of dose, make them an exciting and promising area of research. The 
extensive research into nanoparticle formulations has provided extensive knowledge and 
understanding of such systems and a wide range of techniques to manufacture 
nanoparticles enabling a high degree of control over particle properties. There is however 
a need to perfect pulmonary nanoparticle drug formulations in order to overcome barriers 
to their applications therapeutically, which include safety concerns, physiological barriers 
to delivery of the drug payload, limitations in drug-nanoparticle compatibility which is 
related to low drug-loading efficiencies and scale up issues (Bailey & Berkland 2009). 
 
With the development of new active pharmaceutical ingredients (APIs) that are 
hydrophobic and hence difficult to formulate and manufacture using aqueous systems, the 
application of nanoparticle-based drug delivery systems is increasingly important.  For 
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drug delivery to the lungs, the ability of nanoparticles to increase solubilisation of these 
compounds, control the rate of drug liberation, confer protection from degradation and 
retard or promote drug absorption at the mucosal surface offers many opportunities. The 
development of respirable nanoparticle-based medicines not only requires an 
understanding of aerosol science, but also requires understanding of drug-nanocarrier 
behaviour, particularly for drug compounds with poor aqueous solubility that have 
difficulty being formulated for other delivery routes. 
 
1.3 Aerosolised particle delivery to the lung 
The anatomical structure of the lungs is advantageous for drug delivery due to a very large 
surface area, dense vasculature, lower protease activity (compared to the 
ganstrointestinal tract) and the thin alveolar epithelium making the lungs highly 
permeable to drugs (Scheuch et al. 2006; Bailey & Berkland 2009). The lungs are suitable 
for both local and systemic drug delivery. From a therapeutic standpoint, the potential 
advantages of lung delivery for systemic diseases include a non-invasive delivery system, 
bypassing hepatic metabolism (as per oral formulations) and reproducible absorption 
kinetics as pulmonary delivery is independent of diet and interpatient metabolic 
differences (Patton 1996; Byron & Patton 1994; Labiris & Dolovich 2003). In the 
treatment of respiratory diseases the pulmonary route offers the advantages of delivering 
drug directly to the site of the disease, minimising the risk of systemic side effects and 
potentially offering a rapid response (Labiris & Dolovich 2003). In delivery of particles to 
the lungs, deposition takes place through impaction, sedimentation or diffusion depending 
on factors such as the particle size, density, airflow, breathing rate, respiratory volume and 
the health of the individual (Smola et al. 2008). The region where particles deposit is 
determined by their aerodynamic diameter (Da) (defined as the diameter of a sphere of 
density 1 g/cm3 with a settling velocity that is the same as the particle of interest) which is 
defined by Equation 1.1 where ρ is the mass density of the particle, ρa is the unit density 




     
 
  
   
Impaction typically occurs with large particles (>10 µm) as they do not change their path 
and are typically impacted on the surface of the larger airways at sites where the direction 
of airflow changes, e.g. bifurcations.  Particles of 1-10 µm are predominately deposited by 
sedimentation (particles settling under the influence of gravity) in the bronchiolar region 
of the lung. The transport of particles <1 µm in size tends to be driven by diffusion which 
is time dependant and if not deposited particles of this size are likely to be exhaled. 
Diffusion in this context is the transport of particles from a higher to lower concentration 
and typically occurs in areas of low airflow such as the alveoli (Smyth & Hickey 2011). It is 
generally accepted that particles sized between 1 and 5 µm are well able to reach and are 
deposited in the respirable airways (Bailey & Berkland 2009).  
 
1.4 Nanoparticles for drug delivery to the lung 
Nanoparticles can be formed of the drug itself or can be formed from excipients and used 
as drug carriers either by encapsulation, dissolving or entrapping the active substance or 
drug, adsorbing it to the surface of the particle or by chemically attaching the drug (Sung 
et al. 2007). Nanoparticles have a large surface area to volume ratio, favouring them for 
drug delivery as the increase in surface area leads to an increase in dissolution rate, as 







        
 
Where M is the amount of drug dissolved in time t, D is the diffusion coefficient of the drug, 
S is the surface area of drug, h is thickness of diffusion layer, Cs = saturation solubility of 
drug and Cb is the concentration of the drug in bulk medium. Additionally, particles 
smaller than 1 µm show higher saturation solubility, increasing as the particle size 
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decreases, thus enhancing mass transfer from the nanoparticles to the surrounding 
medium (Muller, R.H., Jacobs, C., Kayser 2001). In addition to these properties, the ability 
of nanoparticles to target delivery and protect drug from degradation make them 
especially suited for drug delivery (Kunda et al. 2013). 
 
In terms of targeting the lungs, the deposition of nanoparticles upon inhalation is driven 
by diffusion due to their small size, which means it is likely they will be exhaled and 
therefore not deposited in the alveolar region of the lung (Kunda et al. 2013).  Long term 
storage of nanoparticles also leads to the formation of poorly respirable aggregates due to 
their high particle interaction (Kunda et al. 2013; Sung et al. 2007). Hence nanoparticles 
are often formulated into respirable microparticles (sized within the range 1 – 5 µm) 
which can reach the desired region of the lungs and deliver a payload of nanoparticles 
(Chang et al. 2003; Tsapis et al. 2002; Sugiyama et al. 2006; Tsapis et al. 2005). 
 
Pandey et al. investigated poly(lactic-co-glycolic acid) (PLGA) nanoparticles loaded with 
anti-tuberculosis drugs for aerosolised drug delivery in guinea pigs and demonstrated that 
a single inhalation resulted in therapeutic levels for up to six days (Pandey et al. 2003). 
This is an example where inhaled delivery of nanoparticles could improve drug 
bioavailability and reduce frequency of dosing. Another example of adopting nanoparticles 
as a means to sustain release of a drug comes from a study by Kawashima et al.  where 
PLGA nanoparticles were loaded with insulin, nebulised and administered to guinea pigs 
(Kawashima et al. 1999). They compared the hypoglycaemic effect of the nanoparticulate 
formulation with nebulised insulin solution and found a prolonged period of 
hypoglycaemia (48 hours) for the nanoparticle formulation compared to 6 hours for the 
insulin solution, suggesting a sustained release property of the PLGA nanoparticles. A 
similar study by Zahoor et al. reported that antitubercular drugs were more effective 
when they were encapsulated in alginate nanoparticles and administered via inhalation to 




Aside from polymers, other materials have also been studied for nanoparticulate drug 
delivery to the lung. Dames et al. (Dames et al. 2007) described the ability to direct 
inhaled, magnetically charged iron oxide nanoparticles to specific areas of the lungs in 
mice without adversely affecting respiratory mechanics, demonstrating that targeted 
nanoparticulate aerosol delivery to the lungs is achievable and could prove to be beneficial 
in the treatment of localised lung infections or tumours by using a targeting approach. 
Lipid-based nanoparticles have also been studied for drug delivery to the lung although 
most published data refer to the identification and evaluation of the desired 
physicochemical parameters of the formulation. However, Pastor et al. developed sodium 
colistimethate loaded lipid nanoparticles for antimicrobial therapy for cystic fibrosis and 
found that they demonstrated a sustained release profile in vitro (Pastor et al. 2014). 
 
Sham et al. introduced the idea of incorporating nanoparticles in a larger microparticle 
matrix with spray-drying two nanoparticle systems (gelatin and iso-butyl cyanoacrylate) 
(Sham et al. 2004). This study proved the concept of delivering nanoparticles to the lungs 
in larger carrier particles. Tsapis et al. developed large porous particles which dissociated 
in physiological conditions to produce polymeric nanoparticles, providing the advantages 
of nanoparticle delivery while also having the convenience of a geometrically large porous 
system with a low aerodynamic diameter that deposited deep in the lung (Tsapis et al. 
2002). 
 
1.5 Formulations, manufacture and delivery devices 
There is a plethora of techniques and processes that have been developed to produce 
respirable microparticles. Nebulisation is one such example. Air-jet nebulisers work by 
generating high velocity air from compressed jets to shear a solution or suspension into a 
film that collapses to form aerosolised droplets (Tiano & Dalby 1996). Ultrasonic 
nebulisers work by vibrating a piezoelectric crystal at high frequencies to generate a mist 
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(Tiano & Dalby 1996). There are also nebulisers that utilise vibrating mesh technology to 
generate a mist. These utilise a mesh or membrane with thousands of holes that vibrate at 
the top of a liquid stock solution/suspension to form a mist of fine droplets through the 
holes (Ghazanfari et al. 2007). Dailey et al. studied the effect of air-jet and ultrasonic 
nebulisation on polymeric nanoparticle suspensions and found the nanoparticles were 
particularly susceptible to aggregation with jet nebulisation, while aggregation was 
reduced with the use of ultrasonic nebulisers (Dailey et al. 2003). Patlolla et al. postulated 
their celecoxib-loaded nanostructured lipid carriers would have greater stability against 
the shear forces generated by nebulisation and upon jet nebulisation found no significant 
changes in stability or drug content (Patlolla et al. 2010). 
 
The most commonly used type of inhaler is pressurised metered dose inhalers (pMDIs). 
These are pressurised cannisters that contain drug either in solution or suspended in a 
liquid propellant. Historically chlorofluorocarbons (CFCs) were used, however due to their 
adverse effect on the ozone layer these are no longer used and hydrofluoroalkanes are 
now typically used (Siddiqui & Plosker 2005). Although nanoparticle-based pMDIs do not 
exist on the market currently, some studies involving nanosized formulations for use with 
pMDIs have been carried out. Chitosan-based nanoparticles were formulated into pMDIs 
to demonstrate their potential as a drug delivery carrier (Sharma et al. 2012), while 
insulin-containing nanoparticles formulated into a pMDI was found to have increased 
stability (due to the use of essential oil excipients) and higher predicted lung deposition 
compared to typical pMDI formulations (Nyambura et al. 2009).   
 
The powder formulations used in dry powder inhalers (DPIs) can be engineered to contain 
nanoparticles.  Spray-freeze drying (SFD) is a technique that has been used for particle 
engineering purposes whereby a drug solution is sprayed into a vessel that contains a 
cryogenic liquid such as nitrogen, causing the droplets to freeze instantly. The resulting 
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droplets are then collected and lyophilised to obtain porous dry powder particles (Pilcer & 
Amighi 2010). Although this technique has the advantage of having the ability to produce 
different sized particles, it can cause irreversible damage to proteins owing to unfolding 
and aggregation, causing instability upon reconstitution of the powders (Shoyele & 
Cawthorne 2006). 
 
Development of microparticulate aerosolised systems often involve spray-drying. Spray-
drying is a process in which dry powders are produced by forcing a fluid phase containing 
dissolved or suspended drug through high pressure nozzles (Bailey & Berkland 2009). In 
brief, a liquid feed stock is prepared and atomised to form droplets, these droplets come 
into contact with a hot gas, resulting in the rapid formation of particles by evaporation. A 
cyclone then separates the dry particles from the hot gas (Pilcer & Amighi 2010). 
Nanoparticles are typically prepared separately and then formulated as a dispersion 
where they will essentially be part of a larger microparticle, but still retain their 
favourable properties such as targeting or enhanced solubility (Vehring 2008) as 
described in earlier sections of this chapter. Spray-drying is a popular avenue due to its 
simplicity, ease of scale-up and applicability for a wide range of drugs making it 
industrially relevant (Bailey & Berkland 2009). A disadvantage of spray-drying is the 
inclusion of large amounts of excipient to maintain powder properties.  
  
1.6 Protein-based nanoparticle systems 
The increased use of engineered nanoparticles in consumer products in recent years has 
raised concerns about their effect on human health (Luyts et al. 2013; Brown et al. 2001). 
It has been reported that long term respiratory exposure to some types of nanoparticles 
may cause serious damage to health such as pulmonary fibrosis, granulomas, hypoxaemia 
and pleural effusion (Bakand et al. 2012; Song et al. 2009; Oberdörster et al. 2005). 
Additionally, it has also been reported that inhaled nanoparticles may pass into the 
systemic circulation and accumulate in secondary organs such as the brain and organs of 
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the digestive system (Hougaard et al. 2015; Geiser & Kreyling 2010). A possible 
mechanism for this involves complex formation of nanoparticles with the lung lining 
proteins to form a ferry boat like transport mechanism. Such an effect has not been 
reported for microparticles due to their larger size (Geiser & Kreyling 2010).  
 
Pulmonary toxicity of nanoparticles has been attributed to factors such as particle size 
(Valavanidis et al. 2008), surface charge and reactivity (Brown et al. 2001; Warheit et al. 
2009; Zhang 2012), high aspect ratio (Tran et al. 2011) and hydrophobicity (Jones et al. 
2014). Several possible mechanisms of nanoparticle toxicity have been suggested, ranging 
from immediate reactions to long term effects (Bakand et al. 2012). Nanoparticles may 
cross cell membranes, enter different compartments of the cell and be a direct cause of cell 
injury owing to their small size (Song et al. 2009; Gojova et al. 2007). The unique surface 
characteristics of nanoparticles may induce reactive oxygen species (ROS) generation- 
leading to free radical formation which promotes tissue inflammation and damage to cells, 
protein and DNA (Zhang et al. 2011). Furthermore, the defence mechanisms of the body 
may not be able to cope with nano-sized material and macrophage function may be 
impaired (Mühlfeld et al. 2008).  A study reported high numbers of “vacuolated 
macrophages” i.e. enlarged macrophages with either finely or coarsely vacuolated 
cytoplasms following treatment with polymeric nanoparticles (Jones et al. 2014). These 
macrophage responses did not appear to be linked to hydrophobicity or pro-inflammatory 
potential but may be a sign of autophagy- a process increasingly associated with exposure 
to nanoparticles (Stern et al. 2012). 
 
The complicated mechanisms of nanotoxicity make it hugely important to gain a better 
understanding of the fate of nanoparticles in the lungs including their biological 
interactions and potential nanotoxicity in order for any drug nanocarrier to be considered 
for clinical development for pulmonary drug delivery purposes.  This means that as well as 
being retained in the lung for the duration required in order to deliver the therapeutic 
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payload, it has to be demonstrated that particles (and by-products) are also effectively 
cleared from the lungs and have no or little associated toxicity i.e. are biodegradable and 
biocompatible. 
 
Protein-based nanoparticulate systems are of particular interest as they have been shown 
to be non-toxic, reproducible and demonstrate ease of manufacture in terms of scale up 
(Farokhzad & Langer 2006). Clearance by natural barriers and defence mechanisms in the 
body such as the blood brain barrier and mucociliary clearance in the lung are major 
challenges that have to be overcome by nanoparticle-based drug delivery systems. 
Proteins tackle this problem due to their ability to modify the biological response to 
nanoparticles (Tezcaner et al. 2016). Plasma lipoprotein, fibrin and fibrinogen have all 
been investigated for this purpose (Vedakumari et al. 2013; Goszczyński et al. 2013; 
Rejinold et al. 2011; Huntosova et al. 2012), however albumin is better suited because of 
its biocompatibility, biodegradability and ability to bind drugs which makes it particularly 
attractive for drug delivery.  
 
Albumin nanoparticulate formulations have been studied for intravenous and intravitreal 
administration and one such formulation (Abraxane®) is commercially available. It is 
indicated for the treatment of metastatic breast cancer in adult patients who have failed 
first-line treatment for metastatic disease. Abraxane® appears to be well-tolerated in 
patients with cancer (Fader & Rose 2009). Abraxane® delivers the drug paclitaxel as a 
suspension of albumin nanoparticles in saline, eliminating the need for a lipid-based or 
solvent vehicle that caused hypersensitivity in patients upon injection (Fader & Rose 
2009). Abraxane® also increases the solubility and circulation time of the drug. In 
addition to alleviating previous concerns with toxicity, Abraxane® was also found to have 
higher intratumoural concentrations in preclinical studies (Gradishar et al. 2005; Nyman 





Albumin is the most abundant protein found in human plasma. Physiologically, albumin 
regulates the plasma osmotic pressure, neutralises any free radicals present in the blood 
and binds and transports several compounds like fatty acids, vitamins, hormones and 
drugs (Hawkins et al. 2008). It is this affinity for several drug compounds that makes 
albumin a popular avenue for drug delivery research (Fujiwara & Amisaki 2013). 
 
Albumin is different to other proteins in terms of superior robustness in stability over a 
wide pH range (pH 5-9) and at high temperatures (albumin can be heated for up to ten 
hours at 60°C without causing any structural changes (Kratz 2008). This illustrates the 
ease of manufacture and handling of albumin that makes it a potentially viable candidate 
as a protein-based drug delivery vehicle. Furthermore, as albumin is an endogenous 
protein, metabolic and homeostatic processes already exist which can be utilised that 
affect drug release from albumin nanoparticles and biodistribution of drug and carrier 
(Bhushan et al. 2017).  
 
1.8 Ligand binding to HSA 
Human serum albumin (HSA) is a monomer of 66 kDa, composed of 585 amino acids. It 
contains three helical domains, each one subdivided into two subdomains; A and B 
(Fujiwara & Amisaki 2013).  
 
The affinity of certain ligands to HSA is an important factor with regard to the distribution 
and the effective concentration of drugs in the blood. The specificity of drug binding to 
albumin can be altered due to overlap with the binding sites of physiologically occurring 
fatty acids, (Figure 1.1) (Fujiwara & Amisaki 2013). It should be noted that the literature 
reports different nomenclatures for fatty acid and drug binding sites.  For example, as 
presented in the albumin map, Figure 1.2, the fatty acid-binding site 7 is commonly known 
as drug-binding site 1 (subdomain IIA), while fatty acid-binding sites 3 and 4 overlap with 
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drug site 2 (subdomain IIIA). The fatty acid binding sites 2,5 and 6 do not generally 
overlap with drug binding sites (Ghuman et al. 2005; Fujiwara & Amisaki 2013). A brief 
overview of the two most important drug-binding sites are presented since they are the 
major candidates for ligand binding. 
 
 
Figure 1.1 Human serum albumin (HSA) coordinated with seven palmitate molecules 
described by X-ray crystallography. The seven fatty acid binding sites are depicted on the 
structure (Fujiwara & Amisaki 2013). 
 
 
Figure 1.2 Map of human serum albumin (HSA) ligand binding sites as determined by X-
ray crystallography (Ghuman et al. 2005). 
 
1.8.1 Drug binding site 1 in defatted HSA 
Drug binding site 1 is a binding pocket within subdomain IIA, containing six helices of the 
subdomain IIA and a loop-helix from subdomain IB. The core of the pocket is mostly 
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apolar, but two clusters of polar residues contribute as well. Phenylbutazone, 
oxyphenbutazone and warfarin are common substrates for this binding site (Ghuman et al. 
2005). All these ligands have a planar group and the apolar cavities of the pocket are 
occupied by them to different extents. Interactions of endogenous compounds such as 
fatty acids with the binding pocket are able to cause a conformational rearrangement, 
which can have a positive or negative influence on drug binding in situ (Ghuman et al. 
2005).  However, when albumin is used as a drug delivery vehicle, fatty acid-depleted 
albumin is generally used to avoid this problem.  
 
1.8.2 Drug binding site 2 
Drug binding site 2 has many structural similarities to drug site 1 since they are both 
hydrophobic pockets with hydrophilic features. Drug binding site 2 also consists of six 
helices of subdomain IIIA, but apart from this it is smaller, and the cavity is structurally 
different. Diazepam, ibuprofen and difflunisal all have high affinity for the core of drug 
binding site 2. Despite its relatively small size, it can host two fatty acid binding sites (sites 
3 and 4) (Sudlow et al. 1975; Yamasaki et al. 1996).  
 
1.8.3 Drug binding assessment 
Spectroscopic methods are a useful tool for studying the binding of a ligand to a protein. 
Among these techniques, fluorescence spectroscopy has been widely applied using two 
main approaches. The first approach uses fluorescent probes (fluorescent fatty acids 
analogues or small fluorescent molecules) whose binding has already been determined 
using a combination of techniques (x-ray crystallography, NMR) (Kragh-Hansen 1988; 
Hamilton 2004). The probes tend to associate with a specific binding site on the albumin 
molecule and form a fluorescent complex. Subsequently, the investigated drug is added to 
the system.  Ideally, the drug will selectively displace the probe at the binding site in 
question causing quenching (decrease) of the fluorescent intensity measured (Oracova et 




The second approach involves monitoring the intrinsic protein fluorescence due to the 
tryptophan, tyrosine and phenylalanine residues (Oracova et al. 1996; Sudlow et al. 1976). 
When a ligand specifically interacts with these residues, it can cause quenching in the 
fluorescent intensity. Generally, fluorescence spectroscopy is a quick and readily available 
technique that offers high sensitivity since small amounts of samples can be measured. It 
is also highly selective. This is useful for expensive drug compounds. On the other hand, its 
high sensitivity renders it susceptible to several factors (such as sample preparation 
variability or temperature) that may result in poor reproducibility. Finally, it can provide 
information only on specific binding sites and cannot give a general overview. Despite 
extensive research into albumin binding, the interpretation of binding and binding 
competition studies with albumin can be difficult given the versatility of the protein. 
Binding assays are complicated when used for proteins with multiple drug or fatty acid 
binding sites.  For example, binding competition between compounds might not only occur 
due to competition for exactly the same binding site, but also between two compounds 
that bind in distinct yet partially overlapping binding sites, as have been identified in 
binding site 1 (Fehske et al. 1982; Kragh-Hansen 1988). Binding to an unknown number of 
secondary binding sites further complicates the characterisation of the drug-protein 
interaction (Sudlow et al. 1976; Yamasaki et al. 1996) as drug binding to one site might 
affect the other due to allosteric interactions between site 1 and 2 (Fitos et al. 1999; Chen 
& Hage 2004).   
 
The techniques mentioned above refer to the study of specific drug-binding site 
interactions. Other simple conventional techniques have been used such as affinity 
chromatography- an HPLC method that utilises the immobilised protein as the stationary 
phase (Mallik et al. 2010) and other techniques based on size-separation principles, such 
as equilibrium dialysis (Sagar et al. 2008). These methods provide an overall affinity 
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assessment of drugs for albumin and are described in more detail in this review (Oracova 
et al. 1996). 
 
The identification of the binding affinity of loaded drug to the building block of the 
nanoparticle is important due to its influence on the drug loading efficiency, the half-life 
and release profile of the drug. Ideally, a loaded drug should exhibit a medium binding 
affinity for albumin. With increasing binding affinity, the drug loading efficiency and half-
life of the nanoparticle might increase, while on the other hand it could impair the drug 
release from the nanoparticle and the drug elimination. This effect has been described 
earlier for the interaction of drugs with serum albumin (Hervé et al. 1994; Kratochwil et 
al. 2002; Valko et al. 2003; Colmenarejo 2003). A positive correlation between binding and 
loading capacity has previously been reported (Oppenheim 1981; Whitehead et al. 1984; 
Lin et al. 2001). This is particularly important in the case of hydrophobic drugs, as albumin 
may enhance the solubilisation of such compounds. 
 
1.9 Drug loading and release  
There has been much interest in albumin nanoparticles as drug delivery systems in recent 
years. Abraxane® was the first FDA approved formulation using an albumin-bound form of 
paclitaxel (size ~130 nm) as a suspension in saline for paclitaxel delivery.It improves the 
drug’s aqueous solubility, reduces side effects and subsequently dramatically improves its 
therapeutic effect against tumours. Researchers have also investigated using albumin 
nanoparticles as a carrier for the delivery of a broad variety of drugs, including ganciclovir 
(Merodio et al. 2000), rose-bengal (Lin et al. 2001), Aspirin (Das et al. 2005), 
hydrocortisone (Zimmer et al. 1994), methotrexate (Taheri et al. 2011) and proteins (Li et 
al. 2018).  
 
The loading mechanism of a particular drug into albumin nanoparticles can influence the 
release profile of the drug. Drugs can be loaded into albumin nanoparticles in two 
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different ways: entrapment/encapsulation of the drug or adsorption interaction. 
According to the first mechanism the drug is incorporated into the particle matrix during 
the preparation procedure. The second mechanism relies on the drug binding/adsorbing 
to the albumin due to physical interactions. Sometimes the incorporation of the drug into 
the particles is via a combination of both phenomena. Currently, there are very few studies 
that investigate in detail the mechanism of drug loading in albumin nanoparticles.  
 
The loading efficiency and the release profile of the albumin nanoparticles are influenced 
by the preparation method used. In most cases, drug loaded albumin nanoparticles consist 
of three components; albumin, a drug and a cross-linker. To prepare the nanoparticles, 
these components can be mixed at different times, leading to the creation of slightly 
different nanoparticles.  
 
Albumin has a structure that is predominantly alpha-helical. The additional or organic 
solvent (desolvating agent) in the formation of albumin nanoparticles unfolds and exposes 
amino groups (Mohammad-beigi et al. 2016). Chemical cross-linking is achieved most 
commonly with the use of glutaraldehyde. The precise mechanism of cross-linking of 
albumin by glutaraldehyde is unknown, however mechanisms have been proposed and 
reviewed by Sokoloski and Royer (Sokoloski & Royer 1984) and have indicated the 
coupling of amino groups in the lysine residues (Sokoloski & Royer 1984; Weber, Coester, 
et al. 2000). Lubig et al. suggested a mechanism involving condensation of the cyclic 
monohydrate of glutaraldehyde and N-alkyl-2,6_dihydroxypiperidines (lysine backbone) 
to yield linear polymeric cross-links (Lubig et al. 1981; Saleh et al. 1989). Sufficient 
stabilisation of the particles via cross-linking ensures the particles do not re-dissolve 
again. The combined effects of the factors involved in the manufacture of albumin 
nanoparticles alter the secondary structure of albumin i.e. reduce the percentage of alpha-
helical structure. These points are important to consider in the development of a 
formulation that requires the drug to covalently bind to albumin, as the overall cross-
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linking of albumin by glutaraldehyde may also be affected, hence it may be useful to add 
the drug to the albumin prior to cross-linking.   
 
There are concerns about the use of glutaraldehyde as it is a cytotoxic compound (Singh et 
al. 2010). Furst et al. studied the toxicity of glutaraldehyde release from BioGlue- a sealant 
used to treat aortic dissections (Fürst & Banerjee 2005). They studied the in vitro toxicity 
in human embryo fibroblasts and mouse myoblasts with cytotoxic effects being observed 
in both cell lines, and the in vivo toxicity was studied in lung, liver and aortic tissue from 
rabbits. Low-grade inflammation was found in the aortic tissue however the application of 
BioGlue to the lung and liver tissue invoked serious high-grade inflammation, oedema and 
toxic necrosis- attributed to the high levels of glutaraldehyde released (Fürst & Banerjee 
2005). Glutaraldehyde has also been shown to cause skin sensitivity upon exposure 
(Wiggins et al. 1989). It should be noted that the amount of glutaraldehyde in the above 
studies is a lot higher than the amount used for the cross-linking of albumin nanoparticles. 
It should also be noted that cross-linked glutaraldehyde is not toxic, however free 
(unreacted) glutaraldehyde in solution may exhibit toxicity, which is why albumin 
nanoparticle suspensions are purified after formation to remove the free glutaraldehyde 
(Weber, Coester, et al. 2000; Bronze-Uhle et al. 2017). 
 
Merodio et al. described three different preparation methods for albumin nanoparticles 
loaded with ganciclovir (Merodio et al. 2000). The first method was to incubate the 
nanoparticles with the drug after their formation, for the second method the drug was 
incubated with albumin prior to the nanoparticle formation and for the last method a 
mixture of all compounds was incubated together followed by the formation of the 
nanoparticles by desolvation with ethanol.  The most effective method in terms of drug 
loading appeared to be the incubation of albumin with the drug prior to desolvation with 
ethanol and the addition of the cross-linker with a loading of 169.2 ± 4.1 µg/mg. The 
lowest loading of 15.5 ± 2.0 µg/mg was achieved when the drug was added post particle 
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formation. It has been shown that the electrostatic interactions regulated by the 
surrounding pH can modify protein’s secondary structure. Therefore, the use of a 
crosslinking agent in order to rigidise the nanoparticles can decrease the accessibility of 
the drug into the binding pockets. Consequently, the incubation of the drug/protein 
solution or drug/protein nanoparticles can be of major importance in the drug loading 
efficiency. 
 
Drug loading post particle formation occurs solely by adsorption to the particle surface 
and possibly into the matrix. Adding the drug before adding the cross-linking agent to 
stabilise the particles can increase the drug loading for particular drugs due to the ability 
of some drugs to covalently bind to the albumin (Merodio et al. 2000). The loading 
efficiency is also highly dependent on the drug and the method used to form the 
nanoparticles. Das et al. report a loading efficiency of 347.14 µg/mg for their aspirin 
loaded albumin nanoparticles for the same preparation method as the ganciclovir 
nanoparticles (Das et al. 2012; Das et al. 2005). Lin et al. report no significant loading 
difference between incubating the drug with albumin prior to particle formation and 
adding the drug post particle formation to manufacture rose-bengal albumin 
nanoparticles (Lin et al. 2001). The ability of the drug to form covalent bonds in the 
presence of a cross-linker, the incubation time and concentration of the cross-linker and 
the affinity of the drug for albumin can all affect drug loading, particle stability and drug 
release (Rubino et al. 1993; Weber, Coester, et al. 2000; Oppenheim 1981; Whitehead et al. 
1984; Lin et al. 2001).  
 
Understanding the mechanism of drug loading into albumin nanoparticles is important for 
a good understanding of the resulting performance of the drug delivery system, i.e. drug 
release and pharmacokinetics. In drug diffusion systems for example, when a drug is 
entrapped into a matrix its release profile generally conforms to the Higuchi equation 
(Higuchi 1963). According to this equation, the cumulative drug release is directly 
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proportional to the square root of time. Additionally, when the drug release is regulated by 
the dissociation of the drug from the protein, a constant release rate can be assumed. In 
the intermediate situation where the incorporation mechanism involves a combination of 
the two, the release is characterized from a quick burst of the drug initially due to the drug 
entrapment and then a slower phase due to dissociation from the protein. Generally, it has 
been demonstrated the entrapment method can offer a high loading capacity (Spector 
1975). Drug release from erodible systems i.e. systems where the matrix undergoes 
degradation could be diffusion-controlled or erosion-controlled, depending on whether 
the drug diffusion is faster than erosion of the matrix (diffusion-controlled) or if the drug 
diffusion rate is low and remains in the matrix (erosion-controlled). Erosion can occur as 
surface erosion or bulk erosion. Surface erosion occurs when the surface of the matrix 
erodes, whereas bulk erosion occurs when water penetrates the bulk of the system, 
resulting in homogeneous erosion of the matrix (Kamaly et al. 2016). Erosion models have 
been summarised in this review (Peppas & Narasimhan 2014). A build up of osmotic 
pressure in a non-swelling system resulting in rupture of the system can also lead to drug 
release (Peppas & Narasimhan 2014; Kamaly et al. 2016). Mathematical modelling of drug 
release from osmotic systems is based on the Kedem and Katchalsky analysis (Kedem & 
Katchalsky 1958). Other mechanisms of drug release have been summarised in these 
review papers (Son et al. 2017; Aguzzi et al. 2010). 
 
There are studies in the literature where drug release from albumin nanoparticles formed 
with cross-linker was shown to be biphasic, with an initial first quick release of the drug, 
followed by a slow-release phase (Merodio et al. 2000; Lin et al. 2001; Das et al. 2005; Das 
et al. 2012). This release profile can be explained by the two locations of the drug in the 
nanoparticle, much like Higuchi kinetics described previously. The initial burst is made up 
of the portion of the drug that is adsorbed on the surface of the nanoparticle. The second 
location of the drug is responsible for the slow release profile observed. This portion of the 
drug is chemically bound to albumin with cross-linkers and can therefore only be released 
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slowly (Merodio et al. 2000). Supporting evidence for this theory can be found from the 
release profile of protein loaded albumin nanoparticles that were stabilised using chitosan 
instead of a cross-linker where the protein was released in a monophasic, sustained 
fashion for up to 8 days. The release profile and speed depended on the chitosan 
concentration (Li et al. 2018).  
 
1.10 Retention and degradation of albumin in the lung 
Although albumin nanoparticles have shown potential as drug carriers to the lungs, 
concerns regarding their toxicity, as well as a lack of information on their clearance 
kinetics, are barriers to their clinical use. Understanding the pharmacokinetics of 
nanoparticles is also required to estimate drug release and administration frequency as 
well as understanding of possible accumulation of the drug carrier within the lungs.  
 
Possible mechanisms for protein clearance from the lungs include mucociliary clearance, 
endocytosis by alveolar macrophages, degradation in alveoli or airways and absorption 
across the alveolar and bronchial epithelium into circulation (Hastings et al. 2004). 
Degradation of proteins may occur via proteases in the alveolar space, and although for 
the majority of proteins this is not a major clearance mechanism in the healthy lung (Ishii 
et al. 1991; Nadel 1990; Hastings et al. 2004) it is important to analyse this step to further 
determine the pharmacokinetic profile of albumin-based formulations.  
 
Despite the fact that different proteases and subtypes have been shown to be expressed in 
the healthy human lung, such as cathepsins (Koslowski et al. 2003) and dipeptidyl 
peptidase 4 (DPP4) (Křepela et al. 1985), the exact types and amounts of these proteases 
has not been fully determined. Furthermore, the protease profile has been shown to 
change dramatically in diseased lungs where levels of enzymes found in the healthy lung 
are largely elevated, whilst other proteases may also become prominent, such as 
metalloproteinases (MMPs) in pneumonia (Chiang et al. 2014), prolyl endopepsidase in 
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smoking and COPD (Braber et al. 2011), and neutrophil elastase during inflammation 
(Kawabata et al. 2002). The comparison of healthy and diseased lung models can hence 
provide information to understand the implications for designing drug treatments 
delivered by protein-based drug carriers for patients. 
 
It is important to note that structural changes induced during the manufacturing process 
of albumin nanoparticles (i.e. crosslinking mentioned earlier in this chapter) may result in 
differing clearance mechanisms compared to albumin molecules. This has been taken into 
account in various studies that have also investigated nanoparticle degradation in the 
presence of various enzymes and the factors that affect the degradation kinetics. Wartlick 
et al. observed that increasing the amount of glutaraldehyde crosslinking in albumin 
nanoparticles reduced the degree of degradation using enzymes trypsin and proteinase K 
(Wartlick et al. 2004). Langer et al. further concluded that the degree of crosslinking 
affects enzyme degradation using enzymes trypsin, protease, proteinase K and pancreatin 
(Langer et al. 2003). Furthermore, the fastest degradation was seen with pepsin at pH 2; 
trypsin, proteinase K, cathepsin B and protease achieved nanoparticle degradation over 24 
h.  
 
The clearance rate of nanoparticles from the lungs also depends on the material and 
physicochemical properties of the nanoparticles used. Lipid nanoparticles (200 nm) were 
shown to rapidly clear from the lungs in rats within the first hour (Videira et al. 2002), 
whilst poly-acrylamide nanoparticles (20-40 nm) remained mainly in the lungs over a 24 h 
period (Liu et al. 2009), and albumin delivered as nanoparticles (200 nm) remained in the 
lungs for > 48 h (Woods et al. 2015). Furthermore, albumin remained for longer in the 
lungs when delivered as nanoparticles compared to a solution. This could be attributed to 
the difference in size and form, which prevents nanoparticulate albumin from utilising the 




1.11 Albumin nanoparticle manufacture 
Weber et al. (Weber, Coester, et al. 2000) evaluated in great detail the well-documented 
“desolvation method“ for the preparation of albumin nanoparticles. In brief, desolvation of 
an aqueous solution of albumin is achieved by dropwise addition of a solvent such as 
ethanol or acetone to the stirred protein solution.  It is a thermodynamically driven self-
assembly process that separates and coacervates the albumin molecules in the aqueous 
phase (Jun et al. 2011). The desolvating agent has a critical effect on the protein’s 
conformation and the morphology of the binding sites. As investigated through Fourier-
transform infrared spectroscopy (FTIR) experiments, the addition of ethanol into aqueous 
solutions of albumin can a) significantly alter its native structure, b) solubilise the protein 
and c) decrease the percentage of α-helical structure (Mohammad-beigi et al. 2016; 
Merodio et al. 2000). As mentioned previously, a cross-linker (usually glutaraldehyde) is 
used to cross-link the amino groups in the nanoparticles to stabilise them so they do not 
solubilise (Zhao et al. 2010). Weber et al. also studied the effect of glutaraldehyde and 
found that increasing glutaraldehyde concentrations reduced the number of available 
amino groups on the albumin surface and lowered the zeta potential but had no effect on 
the size of the nanoparticles. As an alternative to the use of a cross-linker, heat 
stabilisation has also been investigated (Weber, Coester, et al. 2000). This is where instead 
of the addition of a cross-linker, the particles were incubated at different temperatures. 
This process works by heat-induced unfolding, followed by protein-protein interactions 
such as hydrogen bonding, hydrophobic or electrostatic interactions and disulphide-
sulphydryl reaction (Yu et al. 2006; Qi et al. 2010). Weber et al. found heating for less than 
48 hours at 50°C and for less than 24 hours at 60°C did not stabilise the colloidal system, 
confirming that albumin can survive being heated at 60°C for ten hours. Heating for two 
hours at 70°C however showed particles were cross-linked, and heating for more than two 
hours did not affect the extent of cross-linking of the amino groups. This is consistent with 
findings from Chen et al. that showed increasing temperature will increase the degree of 
cross-linking, while also decreasing the rate of dissolution of albumin in water (Chen et al. 
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1994). The size of the nanoparticles formed can be controlled by adjusting albumin 
concentration, pH, and ion content (Jun et al. 2011). The pH of the albumin solution is a 
major factor in determining particle size as the electrostatic interactions regulated by the 
pH of the surrounding medium can modify the protein’s secondary structure (Langer et al. 
2003). Overall, this technique proved to be reproducible and shows ease of scale up.  
Despite the preference to avoid cross-linkers like glutaraldehyde in the manufacture 
process, it is unrivalled in producing the most stable nanoparticles compared to 
alternatives that have been tried.  
 
Other methods of albumin nanoparticle manufacture have been investigated. Nanoparticle 
albumin bound technology (nab technology) is ideal for formulating hydrophobic drugs in 
a nanoparticulate system. It is based on a technique where the drug is dissolved in an 
organic solvent and emulsified in water under high pressure homogenisation using 
protein (albumin) as a stabilising agent. The organic solvent is then removed so the drug 
can precipitate and protein coated nanoparticles can be formed. Abraxane® (nab-
paclitaxel) is the first FDA approved product utilising this technology. This approach has 
been utilised in studies with itraconazole (Chen et al. 2008) and curcumin (Kim et al. 
2017) for intravenous administration. Despite the success of this technology, albumin is 
not the core or matrix of these formulations but rather the main structure of the 
nanoparticles is based on the drug, with albumin acting as a coating stabiliser.  
 
The emulsification method is another popular choice for the preparation of albumin 
nanospheres (Elzoghby et al. 2012). In general, an aqueous albumin solution forms a 
water/oil emulsion with its gradual addition into a continuous oily phase under high-
speed homogenisation or high shearing. Subsequently, the resulting nanoparticles are 
crosslinked by chemical or thermal treatment and the oily phase is removed using organic 
solvents (Patil 2003; Sundar et al. 2010). During chemical treatment a crosslinking agent 
(usually glutaraldehyde) is added after the formation of the emulsion to stabilise the 
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already formed nanoparticles (Sirotkin et al. 2001). Under thermal stabilisation, albumin 
is rendered insoluble after the application of high temperature with the formation of 
interchain amide bonds (Lin et al. 2004). Critical parameters to control the particle size, 
the polydispersity index and the yield, such as the protein concentration and the aqueous 
phase volume, have also been determined for the emulsification technique (Sirotkin et al. 
2001). Regarding the drug loading efficiency of this method, no data was found in the 
literature that provide information on the effect this method’s parameters have on drug 
loading. It can be assumed, as before, that the cross-linking agent can alter the 
conformation of the albumin binding sites and the application of high temperatures can 
also influence the structural integrity of albumin. It should also be considered that 
hydrophobic drugs may partition into the continuous oily phase or perhaps be extracted 
during oily phase removal, resulting in drug loss and subsequent reduction in drug 
loading.  
 
As mentioned above, spray-drying is a well-established method in the pharmaceutical 
industry for producing powders from a liquid phase. The Nano Spray dryer technique 
utilises a vibrating mesh to form fine droplets and particles are collected using an 
electrostatic precipitator. Lee et al. utilised this technique to form spray-dried BSA 
nanoparticles and found the largest determinants in particle size and morphology were 
the spray mesh size and surfactant concentration- for which they used tween 80 (Lee et al. 
2011).  
 
In summary, albumin nanoparticles are considered to be a promising delivery system due 
to their binding capacity for a wide variety of molecular classes, benign toxicological 
profile and potential for controlling the release of active substances. However, it is 
important to extensively evaluate the interactions of a drug candidate (with poor aqueous 
solubility) with albumin and design optimised preparation methods that will allow for 
optimal loading of the drug and reproducible formation of particles. While methods have 
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been adopted that generate particles with reproducible characteristics (particle size 
diameter, size distribution and zeta potential), the drug loading characteristics (binding 
site interactions and solubilisation properties) have been insufficiently characterised so 
far. As well as drug loading, nanoparticle systems for drug delivery must also be able to 
release the active substance at a desired rate. The study of drug release from albumin 
nanoparticle systems is therefore another important area that requires more extensive 
understanding. When it comes to the challenges with aerosolised drug delivery, it is clear 
that some of the most promising advances come from applying nanotechnology to particle 
engineering.  However, the design of such a system requires understanding of drug-
nanoparticulate interaction and the many formulation and technical issues that come with 
the development of inhalable carriers to the lung. The studies discussed here confirm the 
potential of albumin as an effective nano-formulation for drug delivery to the lungs, but 
also highlight the need for further exploration of the development of a viable and effective 
albumin nanoparticulate aerosol formulation for controlled delivery of hydrophobic drugs 





1.12 Aim and scope of thesis 
The overall aim of this thesis was to develop a respirable microparticle formulation 
containing drug-loaded albumin nanoparticles for delivery to the lungs. Taking into 
consideration the factors reviewed in this introduction, the key research questions to 
consider when developing such a system were identified.  a) Can an albumin nanoparticle 
formulation be developed in a way that hydrophobic drug can be satisfactorily loaded, 
stored and released? b) Is the hydrophobic drug delivered effectively using the albumin 
nanoparticle formulation? c) Is it possible to formulate the albumin nanoparticles as part 
of a microparticle for inhaled delivery while retaining their properties?  Ideally albumin 
nanoparticles should be able to load drugs that are typically difficult to formulate, protect 
them until they are required to exert their pharmacological action and sustain drug 
release. The developed inhaled system should be stable and display satisfactory 
aerosolisation properties in order to be effective at delivering drug-loaded albumin 
nanoparticles to the lungs. 
 
The following specific objectives were set in order to fulfil the aim: 
- Establish methods for manufacture of albumin nanoparticles and their impact on 
particle physicochemical properties and stability 
- Investigate the mechanisms of loading and release of model drugs in albumin 
nanoparticles and investigate their efficacy using bioassays 
- Develop prototype formulations for the encapsulation of nanoparticles in 
respirable microcarriers 
- Optimise nanoparticle loading into the preferred respirable formulation and 
evaluate the viability as an inhaled medicine in terms of respirable dose, particle 








Albumin nanoparticles were investigated in this thesis as a potential carrier system for 
drug delivery to the lung. In this chapter, the method development for the manufacture of 
bovine-based albumin nanoparticles and subsequent human serum albumin nanoparticles 
is outlined. The characteristics of nanoparticles produced were explored, as well as the 
stability and digestion of the particles in a clinically relevant model. It was anticipated this 
work would provide the foundation for the development of a respirable formulation 
containing drug-loaded albumin nanocarriers for pulmonary drug delivery.  
 
Albumin nanoparticles are no stranger to the drug delivery field. Albumin nanoparticulate 
formulations have been studied for intravenous and intravitreal administration and as 
mentioned previously one such formulation (Abraxane®) is commercially available. 
Abraxane® utilises “nab-technology” whereby albumin solution and a drug solution are 
mixed under high pressure to form nanoparticles. The albumin supposedly stabilises the 
drug particles at an average size of 130 nm. This method is different to other methods of 
albumin nanoparticle manufacture where albumin nanoparticles are formed via 
desolvation, emulsification, or thermal gelation and drug is typically loaded into them 
(Elzoghby et al. 2012).  
 
Nanocoll® is a commercial product consisting of human albumin colloidal particles. It is 
sold as a powder and is reconstituted with aqueous sodium pertechnetate (99mTc) injection 
solution to create a technetium-99m albumin nanocolloid injection product (O’Brien et al. 
2006). Although not used for drug delivery, it is essentially a radiopharmaceutical used 
intravenously for bone marrow scanning and locally to demonstrate integrity of the 
lymphatic system and for identifying the sentinel lymph node in some types of cancer 
(O’Brien et al. 2006). Nanocoll® has also been used for diagnostic lung imaging and its 
pulmonary deposition patterns have been studied in human subjects after nebulised 




The usefulness of albumin in nanoparticle formulations for anti-cancer applications is well 
documented in the literature. The development of a nanoparticle formulation containing 
albumin for the delivery of doxorubicin and tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL) to tumour cells has also been investigated (Thao et al. 2016) and 
another study showed folate-decorated BSA nanoparticles loaded with paclitaxel could 
target prostate cancer cell lines (Zhao et al. 2010). Other non-cancer therapeutic strategies 
have also been explored, although more of the recent work with albumin in this respect is 
focused on cancer therapy or tumour imaging (Dong et al. 2016; Tang et al. 2016; 
Khandelia et al. 2015). Examples of non-cancer related studies include a study by Mishra 
et al. which demonstrated that modifying the surface of PEG-ylated human serum albumin 
nanoparticles, encapsulated with an anti-viral drug azidothymidine (AZT) by anchoring 
transferrin ligands to it, could target the brain (Mishra et al. 2006). Ganciclovir-loaded BSA 
nanoparticles have been studied for intraocular delivery by intravitreal injection (Merodio 
et al. 2002). Das et al. studied aspirin-bovine serum albumin nanoparticle coacervates for 
the purposes of intraarticular delivery for anti-inflammatory disease in arthritis or 
intraocular delivery for diabetic retinopathy (Das et al. 2005). Li et al. studied BSA 
nanoparticles loaded with sodium ferulate for hepatic targeting (Li et al. 2008).  
 
Despite albumin nanoparticle-based pharmaceuticals being available, and the high 
research interest in utilising albumin nanoparticles as drug delivery vehicles, no systems 
are available or licensed for the inhalation route or for pulmonary drug delivery. The aim 
therefore of this chapter was to establish the manufacturing technique of bovine serum 
albumin nanoparticles, translate this to human serum albumin nanoparticles and 
characterise these for suitability for development as a drug carrier for delivery of 
pharmaceutical agents to the lung. More specifically, the following objectives were set for 
the work in this chapter: 
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- Manufacture BSA nanoparticles using a modified desolvation technique and 
characterise these systems 
- Manufacture HSA nanoparticles for comparison with BSA nanoparticles 
- Study the storage stability of both BSA and HSA nanoparticle suspensions 
- Investigate the breakdown of albumin nanoparticles in a protease model relevant 







Human serum albumin [HSA; isoelectric point 4,7. (Vlasova & Saletsky 2009)] and bovine 
serum albumin (BSA) of molecular weight 65,000 g/mol (fatty acid free) were purchased 
from Sigma-Aldrich (Buckinghamshire, UK). Trypsin (~10000 BAEE units/mg) was 
purchased from Sigma-Aldrich. Phosphate buffered saline (PBS) tablets came from Oxoid. 
Ethanol, water, sodium hydroxide and glutaraldehyde were of HPLC grade and obtained 





2.3.1 Albumin nanoparticle manufacture 
Bovine and human serum albumin nanoparticles were manufactured using a modified 
desolvation method as adapted from Weber et al. (Weber, Kreuter, et al. 2000) and from 
Woods, 2015 (Woods 2015). Albumin (50 mg, fatty acid free) was dissolved in 1.0 mL Tris 
HCl buffer (0.01M, pH 8.9). After the addition of 25 µL NaOH (1M), 4.0 mL of ethanol was 
added drop wise to the stirred protein solution at a rate of 1 mL/min. Nanoparticles were 
cross-linked by addition of 47.2 µL 5% glutaraldehyde in water and overnight stirring. 
Particles were purified by at least 4 cycles of spin filtration [30 kDa molecular weight cut-
off (MWCO)] into PBS. 
  
2.3.2 Nanoparticle physicochemical characterisation 
Particle hydrodynamic diameter and polydispersity index (PDI) was determined by 
Dynamic light scattering (DLS) using the Zetasizer Nano Series ZS (Malvern Instruments, 
Malvern, UK). DLS enables the determination of the diffusion coefficient (D) of a particle or 
droplet in solution (Finsy 1994). Assuming the particles are spherical, they undergo 
random thermal motion called Brownian motion which is modelled by the Stokes-Einstein 
equation (Hassan et al. 2015). The measured D can be used to calculate the hydrodynamic 
diameter, d(H), of the particle/droplet using the equation: 
 
Equation 2.1 
     
  
    
 
 
where d(H) is the hydrodynamic diameter, k is the Boltzman constant, T is temperature, D 
is the diffusion coefficient and η is the viscosity. The analysis was performed at a 
scattering angle of 173° and at 25°C, unless stated otherwise. Detailed descriptions of 
dynamic light scattering theory are documented in the international standard for 
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determination of particle size distribution (ISO13321) and by Dahneke (ISO 1996; 
Dahneke 1983).  
 
Zeta potential was measured in water and PBS and measured at 37°C at a concentration of 
20 µg/mL. The zeta potential is used in colloid chemistry for dispersive systems in liquids 
(such as a nanoparticle suspension) and characterises the electrical double layer on the 
solid/liquid interface i.e. it is related to surface charge- a property all materials possess 
when suspended in a liquid (Birdi 2002; Shaw 1992). The fundamentals of zeta potential 
are well described in colloid chemistry texts (Shaw 1992; Hunter 1981; Lyklema 1991).   
 
2.3.3 Physical stability 
Purified nanoparticle suspensions (in PBS) were stored in different temperature 
conditions (4°C and 25°C). Hydrodynamic diameter and polydispersity index (PDI) were 
used as a measure of stability of nanoparticle suspensions and were measured at regular 
intervals.  
 
2.3.4 Digestion experiments 
The breakdown of albumin nanoparticles was assessed in a model representative of the 
physiological lung. Nanoparticle suspensions (1 mL, 10 mg/mL) were incubated in PBS 
(0.1M, pH 7.4) supplemented with 10.8 mg/mL albumin at 37°C. The receiver fluid was 
supplemented with albumin to mimic the protein concentration in lung lining fluid (Bicer 
2011). Nanoparticle breakdown was determined in the presence and absence of trypsin 
(0.1 mg/mL; ~10 000 BAEE units/mg). This concentration was selected to match lung 
protease concentrations from the literature (Wilson 2005). DLS was used to measure the 
size, polydistribution index (PDI) and derived count rate [kilo counts per second (kcps)] of 
samples withdrawn at various time points from both systems with and without trypsin. 
The derived count rate is a function of size and concentration of scattering particles and 




2.3.5 Transmission Electron Microscopy 
Samples were diluted to 1 mg/mL of albumin nanoparticles (based on initial 
concentration) with ultrapure water. A sample, 3 µl, of suspension was then applied to a 
Pioloform-coated copper grid and allowed to settle for 1 min. Excess suspension was 
blotted away and the grids stained in 1% w/v uranyl acetate for 1 min. The excess was 
blotted and the grid dried before imaging. Grids were examined using a Tecnai T20 
electron microscope. 
 
2.3.6 Statistical analysis 
Statistical calculations were carried out using the software SigmaPlot 14.0 for Windows 
(SyStat Software Inc., CA, USA). To identify statistically significant differences between 
particle size measurements and zeta potential, two-tailed Student t-tests were performed. 





2.4.1 Physical characteristics of nanoparticles 
Table 2.1 shows BSA / HSA sizing data and zeta potential values in different conditions. 
Size was measured at a 1:10 and 1:100 dilution in water and PBS and at the temperatures 
25°C and 37°C, while zeta potential was measured in water and PBS. No significant 
differences were observed between size measurements taken in the different conditions 
tested. All nanoparticle batches had yields greater than 95%, with no significant 
differences between BSA and HSA nanoparticles. The colour of the nanoparticle 
suspensions (brownish) was attributed to the cross-linking by glutaraldehyde. Ma et al. 
found that cross-linking BSA with glutaraldehyde has an effect on its fluorescent 
properties, as observed by the difference in colour between BSA solution and the BSA 
hydrogels formed in their studies (Ma et al. 2016). Visually no differences were observed 
between BSA and HSA nanoparticle suspensions (Figure 2.1).  
 
Zeta potential is the measurement of the electrostatic potential at the electrical double 
layer surrounding a nanoparticle in solution. A zeta potential between -10 and +10 mV is 
considered neutral and values greater than +30 mV or less than -30 mV is considered 
strongly cationic and anionic respectively (McNeil 2011). The effect of pH on the zeta 
potential of BSA in saline has been studied (Salgin et al. 2012). The isoelectric point is the 
pH at which a particle has zero net surface charge i.e. the zeta potential of a substance is 0 
(Jiang et al. 2009). For BSA this has been reported as between pH 4 and 5 in sodium 
chloride at concentrations between 0.001 – 0.1 M (Salgin et al. 2012). At pH values below 
this, the zeta potential will be more positive and at more basic pH it will be more negative 
(Salgin et al. 2012). Zeta potential measurements were carried out at physiological pH (in 
the cases of both water and PBS), with different values observed for both (-23.8 ± 11.7 and 
-10.4 ± 3.3 respectively),attributed to the fact that zeta potential is not only dependent on 




Table 2.1 Hydrodynamic diameter, polydispersity index (PDI) and zeta potential of BSA and HSA nanoparticle suspensions. Data marked with * represent a 





and PDI [units] 
Size 37°C 




and PDI [units] 
Size 37°C 




*100.8 ± 6.5 
[0.122 ± 
0.001] 
*104.4 ± 5.8 
[0.125 ± 
0.016] 









-25.6 ± 8.7 















*100.7 ± 3.3 
[0.109 ± 
0.011] 
*108.3 ± 3.0 
[0.135 ± 
0.016] 
-10.4 ± 3.3 
*110.7 ± 8.3 
[0.009 ± 
0.001] 
*111.3 ± 7.0 
[0.011 ± 
0.001] 
-10.6 ± 2.7 


















Figure 2.1 Bovine serum albumin (BSA) nanoparticles (left) and human serum albumin 
nanoparticle (HSA) suspensions (right).  
 
2.4.2 Stability  
Both BSA and HSA nanoparticle suspensions remained stable at 25°C for three months, 
while at 4°C they remained stable for six months. Nanoparticle suspensions were deemed 
as unstable when visual signs of aggregation were observed. Table 2.2 shows the original 
size and PDI for nanoparticle suspensions tested and after three or six months for storage 
at 25°C and 4°C respectively. No significant differences were observed for the stability of 
BSA vs HSA. 
 
The storage stability of both BSA and HSA nanoparticle suspensions at room temperature 
and 4°C was investigated (Figure 2.2). The stability was assessed by measuring the size 
and PDI of nanoparticle suspensions as well as observing the physical nature of the 
suspensions. No differences were observed visually between BSA and HSA suspensions, 
however for BSA nanoparticles, a significant increase in particle size was observed after 
three months of storage at room temperature, an increase in size was also observed for 
HSA nanoparticles under the same storage conditions however this was not found to be 
statistically significant. Nanoparticles remained of an acceptable size and dispersity for up 
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to one month for nanoparticles stored at room temperature, whereas they remained stable 
for six months upon storage at 4°C.  After these time points, suspensions showed visible  
signs of aggregation and sedimentation. 
 
Table 2.2 Size and PDI data for nanoparticle suspensions after storage at either 25°C or 
4°C for both bovine serum albumin (BSA) and human serum albumin (HSA) nanoparticle 








T = 0 
 
Three months T = 0 Six months 
BSA 
109 ± 1 
 
[0.07 ± 0.01] 
 
122 ± 2 
 
[0.28 ± 0.03] 
112 ± 1 
 
[0.09 ± 0.01] 
132 ± 6 
 
[0.25 ± 0.04] 
HSA 
130 ± 3 
 
[0.08 ± 0.01] 
140.5 ± 5 
 
[0.24 ± 0.06] 
130 ± 8 
 
[0.09 ± 0.01] 
144 ± 5 
 





Figure 2.2 Influence of storage time on particle size and polydispersity of bovine serum albumin and human serum albumin nanoparticles 
At 25°C and 4°C. The bars depict the hydrodynamic diameter (nm, left side axis) of particles and the lines depict the polydispersity index (PDI, right-side 
axis).  Data represent the mean and standard deviation of n = 3 measurements. An asterisk (*, or **, or ***) depicts a statistically significant difference in 




2.4.3 HSA nanoparticle digestion 
Preliminary digestion experiments with BSA nanoparticles were carried out where TEM 
images were taken of nanoparticles treated with trypsin at different time points., in order 
to assess visual evidence of digestion. TEM images of untreated BSA nanoparticles are 
shown in Figure 2.3. Particles appear round and smooth with fairly monodisperse size 
populations. Figure 2.4 shows TEM images at different time points after the addition of 
trypsin to the nanoparticle suspensions.  
 
Figure 2.3 Representative TEM images of BSA nanoparticles suspended in water (top) and 






Figure 2.4 Representative TEM images showing BSA nanoparticles before and after 
exposure to trypsin at time points (hours): 0, 4, 24 and 48. 
 
Digestion studies were subsequently carried out with human serum albumin 
nanoparticles in release medium representative of the lung lining fluid. DLS and PDI data 
were used to evaluate the change in concentration of the nanoparticles. DLS data only gave 
limited information with regard to particle breakdown, as it could not be ascertained if 
whole particles were being detected from the count rate or if larger particles obscured the 
detection of smaller fragments. Nevertheless, a trend was observed where decreasing 
particle count rates (Figure 2.5) and increases in polydispersity (Figure 2.6) were noted 
for samples retrieved from the trypsin system. Albumin nanoparticle breakdown in the 
trypsin system showed an initial rapid decrease in the count rate (concentration dropped 
to 50% after 4 hours) followed by a slower digestion rate for the remainder of the 
experimental period (20% concentration at 48 hours). Nanoparticles remained stable in 




Figure 2.5 Digestion of HSA nanoparticles in PBS supplemented with albumin with and 
without trypsin as a model lung protease. Graph represents the count rate at each time 
point as a percentage of the initial count rate. Data represent the mean and standard 




Figure 2.6 Polydispersity (PDI) of HSA nanoparticle suspensions in PBS supplemented 
with albumin with and without trypsin as a model lung proteaseat time points (hours): 0, 







The characteristics of the BSA nanoparticles manufactured here are in good agreement 
with results from previous studies using similar conditions to form BSA nanoparticles, 
with sizes of 100-200 nm and narrow size distributions (Li et al. 2008; Zhao et al. 2010; 
Bronze-Uhle et al. 2017). Similarly, the data obtained from HSA nanoparticles are also 
comparable to previous studies (Wartlick et al. 2004; Von Storp et al. 2012; Kim et al. 
2009). This size range was chosen because it is within this range the retention and 
potential controlled release properties of the nanoparticles are apparently best and this 
would be beneficial for exploration after incorporation of a hydrophobic drug into the 
formulation (Elzoghby et al. 2012). Initially, experiments were carried out with BSA in 
order to become familiar with the manufacturing of albumin nanoparticles using less 
expensive material. However, the translation from BSA to HSA is important for the future 
development of albumin nanoparticles as a viable formulation strategy for delivery of 
drugs to the lung so it was important to establish any differences between the two 
albumin types in terms of nanoparticle characteristics. HSA is approved by the FDA and 
exists as an endogenous protein, so it is usually substituted for other sources of albumin 
e.g. bovine serum albumin or ovalbumin to minimise the risk of a possible immunological 
response in in vivo experiments for example. HSA was therefore employed for all further 
experiments.  
 
The desolvation method is a well-established methodology for the formation of albumin 
nanoparticles. The effects of pH, rate of addition of desolvation agent and HSA 
concentration have been studies previously (Langer et al. 2003). The pH was found to be 
the most important factor influencing the size of nanoparticles produced, as exemplified in 
an earlier study by Lin et al. where it was found that increasing pH leads to a reduction in 
size of nanoparticles- owing to the isoelectric point of HSA [4.7,(Vlasova & Saletsky 2009)]. 
As the HSA molecules become increasingly ionised, increased electrostatic repulsion 
occurs between particles (Lin et al. 1993). In this thesis, pH 8.9 was used and this was 
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found to be optimal for the target size range of particles (100-200nm) as determined by 
preliminary studies. Other factors affecting the desolvation technique (i.e. rate of addition 
of ethanol and HSA concentration) have previously been reported to have very little effect 
on the properties of nanoparticles produced, thus the current method was found to be 
suitable for future work.  
 
Nanoparticle suspensions showed stability comparable to a previous study by Dreis et al. 
(Dreis et al. 2007). In terms of long term storage (i.e. a year or longer), freezing or freeze 
drying may be a suitable method for obtaining a dry powder, as displayed in a study by 
Zhao et al where BSA-paclitaxel nanoparticle conjugates were spray-dried with mannitol 
as a cryoprotectant (Zhao et al. 2010). Anhorn et al. studied the effects of different 
cryoprotectants on the stability of freeze-dried HSA nanoparticles and found mannitol, 
trehalose and sucrose as suitable cryoprotectants that prevented aggregation as opposed 
to no cryoprotectant being used (Anhorn et al. 2008). 
 
DLS as a method for detecting albumin nanoparticle breakdown in trypsin digestion 
experiments had its limitations, however, trends could be noted in the data. The TEM 
images from the preliminary experiments with BSA show good agreement with the 
findings from this study as particles appear to undergo rapid digestion at the 4-hour 
timepoint, with continued digestion at the 24-hour and 48-hour time points, with a few 
visible in-tact particles. The trends agree with the findings in a previous study where the 
digestion of BSA nanoparticles was studied in the same release media (Woods et al. 2013) 
where release kinetics showed an initial burst effect followed by a slower rate of digestion 
where particles were also largely degraded within 48 h.  
 
In summary, BSA nanoparticles were manufactured successfully, followed by the 
manufacture of HSA nanoparticles whose properties were similar to BSA. HSA is the more 
viable carrier in terms of the development of a pharmaceutical formulation as it is more 
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pharmaceutically acceptable as an excipient. Nanoparticles were produced with 
reproducible size, low polydispersity, and good stability. The breakdown of albumin 
nanoparticles in a mediumphysiologically relevant to the lung was also investigated. This 





In this chapter the methodology and characterisation of albumin nanoparticle 
manufacture was explored. The translation from preliminary studies with BSA to HSA was 
successfully carried out. The physico-chemical characteristics and stability of the 
nanoparticles was also investigated. The work in this chapter will be used to aid future 
assessment of the feasibility of albumin nanoparticles as a drug delivery carrier. More 
specifically, the potential of HSA nanoparticles as drug carriers for drug delivery to the 
lung will be investigated. Therefore, the encapsulation of model drugs will be investigated. 
The loading, release and subsequent activity of the drug-albumin systems will also be 
evaluated. As the intended purpose of the albumin nanoparticle carriers is for drug 
delivery to the lung, the development of a respirable formulation containing these systems 





Chapter 3 Loading, release and activity of benzothiazinone-loaded 




Tuberculosis (TB) is a disease caused by Mycobacterium tuberculosis and it remains a 
global health problem. It principally affects the lungs although it can spread to other parts 
of the body. In 2016 it was estimated that 10.4 million people developed the disease 
globally while 1.7 million people died from it (World Health Organisation 2017). 
Rifampicin and isoniazid are current treatments for TB, however there is an increasing 
number of cases of multidrug-resistant TB that fail to respond to rifampicin and isoniazid 
(Gandhi et al. 2010). This urges the development of new anti-tuberculosis medicines. 
 
8-Nitro-benzothiazinones (BTZs) are a relatively new class of antitubercular agents that 
have been shown to be effective against drug-susceptible, multidrug-resistant and 
extensively drug-resistant strains of Mycobacterium tuberculosis (Christophe et al. 2009). 
Lv et al. report an MIC of < 0.02 µg/mL for one of their investigated BTZ compounds (Lv et 
al. 2018) while Richter et al. report an MiC value of < 0.5nM for one of their synthesised 
BTZ compounds (Richter et al. 2018). They work by inhibiting the mycobacterial enzyme 
decaprenylphosphoryl‐beta‐D‐ribose 2‐epimerase (DprE1)- an essential enzyme for the 
biosynthesis of D-arabinose, a precursor involved in the biosynthesis of cell wall 
components. DprE1 is one of the enzymes involved in catalysing the conversion of 
decaprenylphosphoryl-β-D-ribose (DPR) to decaprenylphosphoryl-β-D-arabinose (DPA) 
(Mikusova et al. 2005). The formation of DPA appears to be the only source of D-
arabinofuranosyl residues in Mycobacterium tuberculosis and therefore the irreversible 
inhibition of this enzyme by BTZs is responsible for their bactericidal action via 
mechanism-based inhibition of the target enzyme (Mikusova et al. 2014). In the first step 
of the inhibition reaction the BTZ binds non-covalently at the catalytic centre of DprE1, 
which reduces the nitro-group under formation of the nitroso-BTZ  resulting in covalent 




BTZs have relatively poor oral bioavailability compared to the current standard TB 
regimen drug compounds which all have oral bioavailabilities >90% while the most 
promising BTZ candidates currently being studies have shown to have bioavailability of 
about 20% (Xiong et al. 2018; Makarov et al. 2014). This has been attributed to their low 
solubility and absorption and metabolism by bacteria in the gut by the reduction of the 
nitro-group to an amine (Makarov et al. 2014; Richter et al. 2018). This is their main 
metabolic pathway though a recent study has shown they are also metabolised by 
reduction of the aromatic benzothiazinone core by erythrocytes through formation of a 
Meisenheimer complex (Kloss et al. 2017). These issues collectively provide a strong 
rationale for exploring alternative formulation strategies and routes of administration to 
improve BTZ bioavailability. An example of this being implemented is shown in a Phase Ia 
clinical trial which is currently underway, in which the oral bioavailability of a spray-dried 
amorphous dispersion of a BTZ compound (PBTZ169) in comparison with the native 
crystalline substance is being studied (Innovative Medicines for Tuberculosis & 
Foundation 2018). Aside from this, little is being done to investigate alternative 




Taking all the above into consideration, it was suggested that soluble albumin or albumin 
nanoparticles are potential vehicles for the delivery of BTZs to their primary site of action, 
i.e. the lungs. BTZs represent the typical model drug candidate for an albumin nanoparticle 
formulation strategy. In addition to the above advantages of using albumin, the potential 
enhanced retention of albumin nanoparticles provides additional incentive as illustrated 
in this study of the biocompatibility, clearance, and biodistribution profiles of albumin 
(Woods et al. 2015) showing that albumin delivered as nanoparticles (~180 nm) 
remained in the lungs of mice for longer compared to albumin delivered in solution with 
lung retention of 64% vs 40.6%, respectively, at 48 hours. In terms of TB therapy, delivery 
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of sufficient localised concentrations of the highly-potent BTZ has the potential to provide 
effective antimicrobial activity, which minimises the possibility of resistance developing 
and offers a reduced duration of treatment; all major tenets in strategies for new TB 
therapeutics (Gawad & Bonde 2018).   
 
Therefore, the aim of the work in this chapter was to investigate the potential of human 
serum albumin (HSA) nanoparticles and HSA solution as a carrier for delivering 
antimycobacterial benzothiazinone (BTZ) compounds to the lungs.  
 
The following specific objectives were set to achieve the aim: 
- Investigate interactions between albumin and model BTZ compounds (Table 3.1) 
using solubilisation and binding studies 
- Manufacture BTZ-loaded albumin nanoparticles and study their characteristics 
- Investigate the drug loading, release and antimycobacterial activity of the 
developed formulations in relevant models. 
 
It was hypothesised that albumin would solubilise the BTZ compounds, thereby enabling 
their formulation, however uncertainty around the release of the drug within a 
therapeutically relevant time period was addressed with in vitro release and 




Table 3.1 Structure and physicochemical properties of the four BTZ compounds  




MW* 359.32 g/mol 
Solubility (aq) 373 µM 
(134 µg/ml) 
MIC** 3.3 µM (1.2 µg/ml) 
IF 274 
 
MW* 387.38 g/mol 
Solubility (aq) 88µM 
(34 µg/ml) 
MIC** 0.8 µM (0.3 µg/ml) 
FG 2 
 
MW* 407.37 g/mol 
Solubility (aq) 2.3 µM 
(0.9 µg/ml) 




MW* 439.39 g/mol 
Solubility (aq) 0.9 µM 
(0.4 µg/ml) 
MIC** 0.07 µM 
(0.07 µg/ml) 
*MW = molecular weight 





Human serum albumin (HSA) (low endotoxin, fatty acid free) was purchased from Sigma-
Aldrich (Dorset, UK). Sodium chloride was obtained from Scientific Laboratory Supplies 
Ltd (Nottingham, UK). Phosphate buffered saline (PBS) tablets were obtained from Oxoid 
Ltd (UK). Ethanol, sodium hydroxide, glutaraldehyde, dichloromethane and dimethyl 
sulfoxide (DMSO) were obtained from Sigma-Aldrich (Dorset, UK). Benzothiazinone 
compounds (IR 20, IF 274, FG 2, and AR 112) were synthesised by Adrian Richter and 





3.3.1 UV analysis of benzothiazinone compounds 
UV calibration curves were prepared for all four BTZ compounds and establishment of the 
limit of detection and quantification of compounds were carried out in DMSO using UV 
spectrophotometry. To determine the absorbance maximum of each compound, a  solution 
of each drug in DMSO (22 µg/mL, 7.5 µg/mL, 6 µg/mL and 2 µg/mL for IR 20, IF 274, FG 2 
and AR 112 respectively) was prepared and scanned over wavelengths from 200-800 nm 
using the Perkin Elmer Lambda 2 UV/Vis spectrophotometer and a quartz cuvette (High 
precision cell, Hellma Analytics). A peak at 347 nm was determined as a suitable 
wavelength for detection of all four drugs. A calibration curve of each compound in DMSO 
was prepared by using a serial dilution (1 in 2 dilutions) within the range 100-0.78125 
μg/mL and taking a single absorbance value at 347 nm until readings within the range 1.0 
to 0.1 were obtained. The linearity of the calibration plots were evaluated using least 
square regression analysis. LOD was calculated using the following formula: 
 




while LOQ was calculated using the formula:  
 





Where σ = standard deviation and S = slope. 
 
Three calibration curves were run on a single day to determine the intra-day sample 
variance. Inter-day sample variance was determined using data from three different days. 
Precision was calculated according to the following equation: 
Equation 3.3:                 
  
    





3.3.2 Determination of Benzothiazinone-albumin interactions by solubilisation 
Stock solutions of HSA (fatty acid-free, Sigma-Aldrich, Germany) in water and Tris buffer 
respectively (50 mg/mL) were prepared. Negative controls consisted of water and Tris 
buffer without HSA.  HSA solutions and negative controls (1 mL) were added to separate 
vials containing 0.5 mg BTZ compound and incubated at 37°C for a total of six days. 
Samples of the supernatant (i.e. the wash product obtained upon purification of 
nanoparticles) were removed at pre-determined time points and UV absorbance readings 
were taken at 347 nm. The amount of drug dissolved by each solution was determined 
from the calibration curve and calculated as a percentage of the original drug content. 
A further experiment was carried out with a modified design, which involved dissolving 
the BTZ (0.5mg) first in a volatile solvent (dichloromethane), adding the BTZ solution to a 
glass vial and evaporating the solvent to form a thin film of drug prior to incubation with 
HSA. This was implemented as a means of increasing the rate of solubilisation by 








        
Where M is the amount of drug dissolved in time t, D is the diffusion coefficient of the drug, 
S is the surface area of drug, h is the thickness of the diffusion layer, Cs is the saturation 
solubility of the drug and Cb is the concentration of drug in the bulk medium. Inspection of 
the equation reveals an increase in surface area increases dissolution rate. Although the 
aim here is not strictly dissolution as such, the principles still apply to the solubilisation of 
drug by albumin as is trying to be achieved here. The same experiment was carried out by 
incubating the BTZs in Tris buffer without HSA. 
 
3.3.3 Drug-binding studies to Sudlow’s site I via tryptophan quenching 
BTZ binding to the albumin drug binding site I (or Sudlow’s site I), i.e. the hydrophobic 
pocket, was assessed through tryptophan quenching studies (Abou-Zied & Al-Lawatia 
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2011). HSA solution (1 mL, 1 µM) was prepared in 1:1 saline (25 mM) and Tris buffer (25 
mM, pH 7.4).  Stock solutions (1 mL, 500 µM) of BTZ compounds, ibuprofen (negative 
control) and bilirubin (positive control) were prepared in DMSO. The emission spectrum 
of HSA tryptophan fluorescence was measured between 300 nm to 400 nm with an 
excitation wavelength of 285 nm and an emission slit of 10 nm using a Perkin Elmer LS 
50B Fluorescence spectrometer and a quartz cuvette (Hellma Analytics). Initial 
fluorescence readings were taken for the HSA solution, followed by subsequent readings 
after sequential additions of 1 µL of drug in DMSO. The maximum emission value 
(arbitrary units) of tryptophan fluorescence for each titration was divided by the emission 
value of HSA solution and results were presented as the percentage of tryptophan 
quenching versus drug concentration. 
 
3.3.4 Benzothiazinone-loaded albumin nanoparticle manufacture via pre-loading method 
BTZ-loaded albumin nanoparticles were manufactured using a modified desolvation 
method (Weber, Kreuter, et al. 2000). HSA solution (1 mL, 50 mg/mL) was incubated with 
0.5 mg of BTZ compound for 24 hours at room temperature in a glass vial (vial I). 
Following incubation, the BTZ-saturated HSA solution (1 mL) was removed from vial I and 
placed in a clean vial (vial II). After the addition of 25 µL NaOH (1M), 4.0 mL of ethanol 
was added drop wise to the stirred protein solution. Nanoparticles were cross-linked by 
addition of 47.2 µL 5% glutaraldehyde in water, stirred overnight to remove ethanol, and 
then purified using at least 4 cycles of spin-filtration (30 kDa MWCO) into saline (0.9%) 
solution. The washing fluid was collected for BTZ quantification (vial III). HSA 
nanoparticles without drug were prepared as controls. 
The BTZ content in vials I-III was quantified by UV spectroscopy and expressed as a 
percentage of the original drug content (~0.5 mg).  The mass balance of the drug was 
calculated from the process to determine the drug recovery from the experiment. 
Encapsulation efficiency (EE) and drug recovery were calculated according to Equation 3.5 




Equation 3.5:  
       
  
  
      
Equation 3.6 
                   
        
  
      
Where W0 is the mass of initial drug introduced in the nanoparticle manufacture process, 
w1 is mass of drug in purified nanoparticles, w2 is mass of drug in washing fluid and w3 is 
mass of residual drug. 
 
3.3.5 Benzothiazinone-loaded albumin nanoparticle manufacture via in-situ loading 
BTZ compound (0.5 mg) was weighed in a glass vial (vial I) and dissolved in 
dichloromethane and ethanol (1:10, 4.4 mL). HSA solution in Tris buffer (1 mL, 50 mg/mL) 
was prepared in a glass vial (vial II). After the addition of 25 µL NaOH (1M) to the HSA 
solution, the BTZ mixture was added drop wise to the stirred protein solution. 
Nanoparticles were then cross-linked and purified in the same manner as described above. 
The washing fluid was collected for BTZ quantification (vial III). BTZ content in vials I-III 
was quantified and mass balance was calculated as described above for Method I. 
 
3.3.6 Physicochemical characterisation of nanoparticle suspensions 
The size, zeta potential and physical stability of nanoparticle suspensions were 
determined as described in Chapter 2. 
 
3.3.7 Benzothiazinone extraction from albumin formulations 
BTZ was extracted from nanoparticle suspensions using an optimised organic phase 
extraction method using dichloromethane. Zinc sulphate (850 µL, 0.1M) and ammonia 
solution (200 µL, 10%) were added to 1mL of nanoparticle suspension (50 mg/mL). 
Dichloromethane (5mL) was added to the mixture and sonicated in a water bath for 20 
minutes and left to stand for 60 minutes. Upon phase separation, the denser organic 
dichloromethane layer was carefully drip-separated from the aqueous buffer phase and 
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allowed to evaporate at room temperature overnight. This process was repeated two 
further times. The dried sample containing BTZ was dissolved in 1 mL DMSO and analysed 
by UV spectroscopy. 
 
3.3.8 Benzothiazinone release studies 
BTZ release profiles from selected nanoparticle systems were determined in phosphate-
buffered saline (0.1 M, pH 7.4) supplemented with 10.8 mg/mL albumin at 37°C. The 
receiver fluid was supplemented with albumin to mimic the protein concentration in lung 
lining fluid (Bicer 2011). BTZ release was determined in the presence and absence of 
trypsin (0.1 mg/mL). This concentration was selected to match lung protease 
concentrations from the literature (Wilson 2005). Nanoparticle suspensions (10 mg/mL, 1 
mL) were placed in dialysis tubing (Fischer, MWCO 10 kDa), and then the dialysis 
membranes were immersed in beakers containing 10 mL release buffer. The beakers were 
incubated at 37°C under gentle stirring (100 strokes/min) in a water bath (Grant 
Instruments, Cambridge, UK). The release buffer was withdrawn from the beaker and 
replaced with fresh release buffer at regular intervals to maintain sink conditions. The BTZ 
concentration in each collected release buffer sample was determined by UV spectroscopy. 
BTZs were extracted from the release buffer through organic phase partitioning. 
Dichloromethane (10 mL) was added to the medium, sonicated for 20 minutes and left to 
stand for 60 minutes. Upon phase separation, the denser organic dichloromethane layer 
was carefully drip-separated from the aqueous buffer phase and allowed to evaporate at 
room temperature overnight. This process was repeated two further times. The dried 
sample containing BTZ was dissolved in 1 mL DMSO and analysed by UV spectroscopy. 
Similarity factors (f2) comparing drug release profiles were calculated according to 
Equation 3.7, whereby f2 values between 50 - 100 represent less than 10% difference 
between released BTZ at each time point measured (i.e. similarity) and values <50 are 
considered dissimilar (Gómez-mantilla et al. 2013). The closer the f2-value is to 100, the 





              
 
 
        
 
 
   
 
    
      
Rt = BTZ concentration (%) in release buffer at time point t, Method I systems; Tt = BTZ 
concentration (%) in release buffer at time point t, Method II systems; n = number of time 
points. 
 
3.3.9 Antimycobacterial activity assay in infected macrophages 
These experiments were performed by collaborators Natalja Redinger and Ulrich Schaible 
of Forschungszentrum Borstel–Leibniz Lung Centre and the German Centre for Infection 
Research in Borstel. Murine bone marrow derived macrophages (mouse strain C57BL/6 J) 
were seeded at 1 × 105 cells in 48-well plates in culture medium [Dulbecco’s modified 
eagle medium (DMEM) plus 10 % foetal bovine serum (FBS), 100 µg L-glutamine]. The 
cells were incubated with M. tuberculosis H37Rv (at 37°C, 5% CO2) for two hours then 
washed with culture medium to remove the extracellular mycobacteria. The Multiplicity of 
Infection (MOI) was 2:1 (mycobacteria: macrophage). Albumin nanocarrier formulations 
containing BTZs were incubated for 72 h with infected macrophage cells at three 
concentration levels (final concentration 36, 3.6, and 1.1 µg/mL for IR 20 in DMSO, 
albumin and albumin nanoparticles respectively; and 4.1, 1.2, and 0.1 µg/mL for FG 2 in 
DMSO, albumin and albumin nanoparticles respectively; n=3 independent experiments). 
Vehicle controls were BTZ-free equivalent concentrations of DMSO (4, 2 and 1%), HSA 
solution (5.8, 0.6 and 0.2 mg/mL) or unloaded HSA nanoparticles (1.3, 0.1 and 0.04 
mg/mL). The number of intracellular bacteria was determined by colony counts after 





3.3.10 Statistical analysis 
Statistical calculations were carried out using the software SigmaPlot 14.0 for Windows 
(SyStat Software Inc., CA, USA). To identify statistically significant differences between 
particle size measurements and zeta potential, two-tailed Student t-tests were performed. 
To identify statistically significant differences for all other data, a two-way ANOVA was 







3.4.1 UV analysis of benzothiazinone (BTZ) compounds 
All BTZs were scanned over the UV range of the wavelength spectrum (Figure 3.1). The 
wavelength 347 nm was deemed as suitable wavelength for detection of all four BTZ 
compounds and calibration curves were constructed accordingly. Calibration curves for all 
four BTZ compounds (Figure 3.2) showed excellent linearity over the concentration range 
measured with R2 values > 0.999. LOD and LOQ values for the four BTZ compounds are 
shown in Table 3.2. The average intra and inter-day variation for all BTZ compounds 
complied with the acceptance criteria proposed in analytical guidelines [Relative standard 









Figure 3.2 UV calibration curves for benzothiazinone (BTZ) compounds in DMSO. Results 
represent the mean and standard deviation of n = 3 experiments. 
 
 
Table 3.2 Limits of detection (LOD) and limits of quantification (LOQ) (µg/mL) for 
benzothiazinone compounds.  
Benzothiazinone compound Limit of detection (LOD) 
(µg/mL) 
Limit of quantification 
(LOQ) (µg/mL) 
IR 20 1.37 4.16 
IF 274 0.51 1.55 
FG 2 2.58 7.82 
AR 112 1.19 3.59 
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Table 3.3 Intra-day and inter-day variation in benzothiazinone (BTZ) absorbance as a function of concentration in DMSO. Intra-day variation data obtained 
from three days using the same standards (n=3). Inter-day variation data obtained over three days (n=9) 
Concentration 
(µg/mL) 
Coefficient of variation (%) 
IR 20 IF 274 FG 2 AR 112 
intraday interday Intraday Interday intraday Interday Intraday interday 
100 0.086281 3.190398 0.04953 0.735506 0.621388 1.123596 0.114155 0.540299 
50 0.955763 4.558028 0.809098 2.268602 0.390625 2.253564 0.91886 0.9781 
25 0.498753 1.589058 0.144458 1.578339 1.5822 1.714902 3.952205 3.125 
12.5 0.584512 2.651141 0.749064 3.971806 0.24638 4.418861 0.252486 3.204598 
6.25 2.157871 3.172254 3.569853 1.665433 0.605612 4.014687 0.319567 2.039105 
3.125 0.347104 2.172019 1.197605 2.146161 0 1.547097 0.360094 2.453988 
1.5625 0.388352 2.599043 0.391867 2.041236 0.405633 1.432339 0.408503 1.055893 
0.78125 0.391867 2.141391 0.413377 1.428571 1.63401 1.078253 0.729927 0.724638 
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3.4.2 Benzothiazinone-albumin solubilisation  
The temporal profile of BTZ solubilisation by HSA was initially assessed over a six-day 
period (Figure 3.3A). The solubility profile of the compounds in Tris and HSA solutions 
was assessed to determine whether drug solubilisation by albumin can occur in a buffer 
solution at pH 8.9, as used to generate albumin nanoparticles. Absorbance values of AR 
112 were negative at all albumin concentrations tested, indicating that the amount of AR 
112 dissolved in HSA was undetectable using this method.  
 
Only one of the BTZ compounds (IR 20) was found to be soluble in tris buffer (IR 20). 
Originally, IR 20 was found to have a solubilisation of 2.7 ± 0.5% which corresponds to 
0.25 µg drug (data not shown). 
 
47.0 ± 1.0% IR20 was dissolved by albumin over the six-day period resulting in an 
approximate drug loading of 0.5% (w/w), while only 8.4 ± 0.8% and 4.5 ± 0.8% IF274 and 
FG2 respectively was solubilised under the same conditions, corresponding to a drug 
loading of 0.08% and 0.05% respectively. For IR 20, significant differences were observed 
between solubilisation in HSA vs Tris only from time point t = 1 day onwards. For IF 274, 
significant differences were observed in the extent of solubilisation in HSA vs Tris only 
from time point t = four days onwards. The extent of solubilisation of the most soluble BTZ 
compound IR 20, the poorer solubilisation of IF 274 & FG 2 and the non-detection of AR 
112 suggest poor solubility needs to be overcome in order to maximise interactions 
between the BTZs and albumin. 
 
To overcome the poor solubilisation profile of the BTZ compounds tested a modified 
approach to the experiment was carried out using a film-forming approach (Figure 3.3B). 
Upon using the optimised film-forming method, the solubilisation of IR 20 increased to 7.8 
± 0.1%. No solubilisation in Tris buffer was detected for the remaining three BTZ 
compounds. The extent of solubilisation by HSA of IR20 and IF274 increased to 55.6 ± 
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0.6% and 39.0 ± 4.9% respectively. FG 2 solubilisation also increased to 26.1 ± 3.8%. AR 
112 solubilisation was detectable at 10.1 ± 0.4%. These values correspond to the drug 
loading capacities shown in Table 3.4. It also took 1-3 days to reach maximum 
solubilisation as opposed to the original method where it took up to six days. Statistically 
significant differences were observed for IR 20, IF 274 & FG 2 compared to the control for 
time points t = 1 day onwards. No statistically significant differences were observed for 
solubilisation after t = 1 for all BTZ compounds compared to further time points. Hence it 







Figure 3.3 Time dependent solubilisation profiles of BTZ compounds(500 µg) in 1 mL HSA 
in tris buffer pH 8.9 (50 mg/mL) by (A) original method and (B) film-forming method. 
Results are expressed as a percentage of the original mass (500 µg) at t=0. Results 
reported are from n=3 experiments.  
 
Table 3.4 Solubilisation of BTZ compounds with HSA reported as mass ratios. Values 
reported are the mean and standard deviation from n = 3 experiments. 
Drug BTZ (µg) per HSA (mg) Solubilisation (% w/w) 
IR 20 56 ± 0.6 5.6 
IF 274 39.5 ± 4.9 4.0 
FG 2 26.1 ± 3.8 2.6 






A further experiment was carried out using a micronised form of IR 20 (particle size ~5-
10 µm) to compare with the original non-micronized IR 20 to see whether a further 
increase in the extent of solubilisation by HSA would occur. In this case, there was no 
significant difference observed between milled and non-milled IR 20 in the degree of 
solubilisation by HSA (Figure 3.4).  
 
 
Figure 3.4 Solubilisation profiles of IR 20 Vs IR 20 (milled) using a film-forming approach 
in 1mL HSA in tris buffer pH 8.9 (50 mg/mL). Results are expressed as a percentage of the 
original mass (500 µg) at t=0. Results reported are from n=3 experiments.  
 
 
3.4.3 Benzothiazinone binding to Sudlow’s site I 
Drug interactions with the two principal binding sites of HSA, i.e. site I in subdomain IIA 
and site 2 in subdomain IIIA are considered the major factors in determining the ratio of 
free, active drug concentration versus the protein-bound reservoir (Zsila et al. 2011).  
Thus, characterisation of drug binding to these sites may determine the effectiveness of 
HSA as a drug carrier. Sudlow’s site I is a hydrophobic pocket which contains a tryptophan 
residue (Trp- 214), which contributes to the intrinsic fluorescence of albumin. Drug 
binding reduces the intrinsic fluorescence of this tryptophan and can be used to 
characterise drug binding to site I. Compared with ibuprofen, which does not bind to site I, 
and bilirubin, which shows a strong affinity to site I (Sudlow et al. 1975), the four BTZ 
compounds showed moderate affinity to the hydrophobic binding pocket of albumin with 
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a rank order of: ibuprofen < IR 20 = IF 274 < FG 2 < AR 112 << bilirubin (Figure 3.5).  
Based on these data, it may be inferred that all BTZ compounds studied had a weak affinity 
for site I.   
 
Figure 3.5 Quenching of tryptophan fluorescence indicating the affinity of BTZ binding to 
Sudlow’s site I of HSA. Ibuprofen and bilirubin have been included as negative and positive 
controls, respectively. Data represent mean and standard deviation; n=3 experiments. 
 
3.4.4 Benzothiazinone extraction optimisation 
To validate the quantification method and “track” the fate of the BTZ in solubilisation and 
nanoparticle manufacture processes, extraction of the BTZ was carried out. IR 20 was 
initially extracted from Tris buffer. The solution was prepared by incubating IR 20 (0.5mg) 
with 1mL Tris buffer (pH 8.9) for 24 hours, centrifuging the sample for (Heraeus 
microfuge® pico, DJB Labcare, UK) at 2000 revolutions per minute (RPM) for two minutes 
and removing the supernatant. Extraction was then attempted with the sample. The 
residual drug left behind in glassware was also quantified. UV spectroscopy was used to 
calculate how much IR 20 was solubilised by Tris as described earlier. Figure 3.6 shows IR 
20 recovery from Tris solution in two different conditions: initially by extraction with the 
addition of 2ml dichloromethane and (A) vortexing the mixture for 30 seconds, compared 
to (B) sonicating the mixture for 20 minutes. In both instances the extraction procedure 
was repeated once. By vortexing, 3.9 ± 0.9% was extracted from the sample, compared to 
the expected 9%. Unextracted sample was still detectable from the IR 20 in Tris solution. 
Upon employing sonication, the expected 9% IR 20 was extracted from the sample and IR 
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20 was unable to be detected from the solution. Total mass balance was 75 ± 0.9% and 79 
± 0.9% for (A) and (B) respectively. Following these findings, sonication was employed for 
all further extraction procedures.  
 
 
Figure 3.6 Recovery of BTZ compound IR 20 from tris buffer (1mL; pH 8.9) with 
dichloromethane (2mL) by (A) vortexing for 30 seconds vs (B) sonication for 20 minutes. 
Two rounds of extraction were carried out for both. Expected recovery (%) of IR 20 was 
determined as the proportion of drug solubilised by Tris (determined by UV analysis). The 
remaining fraction expected to be recovered was the “residual” fraction i.e. drug left 
behind in glassware. “unextracted” refers to drug not extracted from the solution. Data 
represent mean and standard deviation of n = 3-5 experiments. 
  
 
Upon successful extraction of BTZ from Tris solution, extraction was carried out from IR 
20 in HSA solution using the same method (Figure 3.7A). 42.0 ± 4.0% IR 20 was extracted 
from the solution, compared to the expected 64%. The experiment was repeated by 
carrying out three rounds of extraction, as opposed to the original two (Figure 3.7B). This 
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slightly increased the amount of IR 20 extracted from the solution to 47 ± 0.5%. Total 
mass balance was 61% ± 3% and 72 ± 3% for (A) and (B) respectively. 
 
Figure 3.7 Recovery of BTZ compound IR 20 from albumin solution in tris buffer (1mL; pH 
8.9) with dichloromethane (2mL) by (A) sonication for 20 minutes with two round of 
extraction vs (B) three rounds of extraction. Expected recovery (%) of IR 20 was 
determined as the proportion of drug solubilised by HSA (determined by UV analysis). The 
remaining fraction expected to be recovered was the “residual” fraction i.e. drug left 
behind in glassware. “unextracted” refers to drug not extracted from the solution. Data 
represent mean and standard deviation of n = 3-5 experiments. 
 
 
To optimise the extraction further, zinc sulphate (0.1M) and ammonia solution (10%) was 
added to the IR 20 HSA solution prior to extraction with dichloromethane. This method 
comes from drug extraction from human serum (Bouzas et al. 2009). Upon employing this 
added step, 57.7% of IR 20 was extracted from the HSA solution, (from a theoretical 62%) 
(Figure 1.8A). This sufficiently optimised extraction procedure was carried out for the 
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other three BTZs (IF 274, FG 22 and AR 112) in HSA solution. Sufficient levels of BTZ (> 
90% of the expected values) were extracted from these solutions with little to no BTZ 
being quantified as unextracted (Figure 1.8B-D). Mass balances for IF 274, FG 2 and AR 
112 were 68% ± 0.6, 61% ± 1, 74% ± 1 and 97% ± 2. Residual fractions of BTZs were 
difficult to quantify as drug loss occurred during processing (i.e. with pipette tips, vials 
etc.).  
 
Figure 3.8 Recovery of all four BTZ compounds (A-D; IR 20, IF 274, FG 2 and AR 112 
respectively) from albumin solution in tris buffer pH 8.9 with zinc sulphate (0.1M) and 
ammonia solution (10%) and dichloromethane (2mL), with three rounds of extraction. 
Expected recovery (%) of IR 20 was determined as the proportion of drug solubilised by 
HSA (determined by UV analysis). The remaining fraction expected to be recovered was 
the “residual” fraction i.e. drug left behind in glassware. “unextracted” refers to drug not 




Finally, the extraction was carried out with IR 20-loaded albumin nanoparticles (Figure 
3.9A). Despite 10.2% IR 20 washing off the nanoparticles with the supernatant fraction, 
only 36.3% of IR 20 was extracted from the nanoparticles, with 15% of drug being 
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unaccounted for. Thus, the amount of dichloromethane used for each round of extraction 
was increased from 2 to 5ml. This increased the IR 20 extraction to 45.5%, and majority of 
the drug was accounted for. Total mass balances for (A) and (B) were 72 ± 3% and 82 ± 
1% respectively. The optimised method carried forward for all future extraction work was 
therefore carried out with following conditions: 3 rounds of extractions by sonication for 
20 minutes with 5mL dichloromethane, zinc sulphate solution and ammonia solution.  
 
Figure 3.9 Recovery of BTZ compound IR 20 from albumin nanoparticle suspensions 
(1mL) by three rounds of extraction with zinc sulphate (0.1M) and ammonia solution 
(10%) using (A) 2mL dichloromethane vs (B) 5mL dichloromethane. Expected recovery 
(%) IR 20 from pre-loaded nanoparticles was determined as the proportion of drug 
solubilised by albumin (determined by UV analysis) and hence introduced into the 
manufacturing process. The remaining fraction was expected to be recovered from the 
“residual” fraction i.e. drug left behind in glassware. “wash buffer” refers to the wash 
obtained during the purification of nanoparticles. Data represent mean and standard 





3.4.5 Benzothiazinone-loaded albumin nanoparticle manufacture: pre-loading (method I) 
and in-situ loading (method II) 
 
BTZ-loaded HSA nanoparticles were prepared using two different modifications of a 
reported desolvation method (Weber, Kreuter, et al. 2000): Method I (Figure 3.10), in 
which the HSA was incubated with BTZ compounds prior to nanoparticle formation and 
Method II (Figure 3.12), in which the BTZ was dissolved in dichloromethane and added to 
the HSA during the precipitation step. Drug encapsulation efficiencies were significantly 
higher with Method II (Figure 3.13) in all cases except for IR 20, which showed similar 
BTZ encapsulation regardless of the manufacturing method (Table 3.5). The amount of 




Figure 3.10 Schematic of production of BTZ-loaded albumin nanoparticles via a pre-





Figure 3.11 BTZ encapsulation efficiency (a) for nanoparticles manufactured via a pre-
loading method (method I). BTZ encapsulation efficiency is compared to drug found in 
wash buffer (b) and residual drug left behind in glassware (c). Data represent the mean 
and standard deviation of n = 3 nanoparticle batches. 
 
Table 3.5 Comparison of encapsulation efficiencies (%) between manufacturing methods I 
and II. Data represent the mean ± standard deviation of n=3 nanoparticle batches. Asterisk 
denotes statistically significant difference between the two method (* P<0.05, ** P<0.01, 
*** P<0.001). 
BTZ 
Encapsulation efficiency (%) Mean BTZ:HSA (μg/mg) 
Method I Method II Method I Method II 
IR 20 53 ± 7 50 ± 3 5.3 ± 1 5.0 ± 0 
IF 274 55 ± 2 60 ± 2* 5.5 ± 0 6.0 ± 0 
FG 2 19 ± 3 53 ± 3*** 1.9 ± 0 5.3 ± 0 





Figure 3.12 Schematic of production of BTZ-loaded albumin nanoparticles via an in-situ- 
loading method (method II) 
 
 
Figure 3.13 BTZ encapsulation efficiency (a) for nanoparticles manufactured via an in-situ 
method (method II). BTZ encapsulation efficiency is compared to drug found in wash 
buffer (b) and residual drug left behind in glassware (c). Data represent the mean and 
standard deviation of n = 3 nanoparticle batches. 
 
 
Size distributions were unimodal with low polydispersity. Visually, nanoparticle 
suspensions varied slightly in colour (Figure 3.14), according to the colour of the BTZ 
compounds they contained. Nanoparticle size and zeta potential measurements were 
equivalent in nanoparticles with and without BTZ encapsulated (Table 3.6).  No significant 






Figure 3.14 Benzothiazinone-loaded albumin nanoparticle suspensions (from left to right): 
control, IR 20, IF 274, FG 2 and AR 112.   
 
 
Table 3.6 Hydrodynamic diameters (nm) and zeta potential (mV) values of BTZ-loaded 
nanoparticles for method I and method II.  Data represent the mean ± standard deviation 






Storage stability of BTZ-loaded albumin nanoparticle suspensions manufactured by both 
methods was assessed by measuring the size and polydispersity index of the suspensions 
at different time points after storage at 4°C and 25°C. Colloidal stability of the nanoparticle 
suspensions was maintained for up to six months at 4°C for both methods of manufacture 
(Figure 3.16 and Figure 3.18). No significant differences were observed between control 
BTZ 
Size (nm) Zeta potential (mV) 
Method I Method II Method I Method II 
IR 20 170 ± 11 179 ± 6 -26 ± 3 -31 ± 2 
IF 274 168 ± 9 168 ± 6 -30 ± 2 -32 ± 2 
FG 2 169 ± 5 178 ± 9 -31 ± 4 -29 ± 2 
AR 112 175 ± 5 167 ± 9 -27 ± 2 -31 ± 3 
Blank 174 ± 7 169 ± 7 -31 ± 3 -31 ± 3 
77 
 
and BTZ-loaded albumin nanoparticle suspensions for all conditions tested. No differences 
were observed between BTZ formulations, nor between manufacturing methods. BTZ-
loaded albumin nanoparticle suspensions remained stable at room temperature for up to 





Figure 3.15 Influence of storage time at 25°C on particle size and polydispersity of benzothiazinone-loaded human serum albumin nanoparticles 
manufactured by method I. The bars depict the hydrodynamic diameter (nm, left side axis) of particles and the lines depict the polydispersity index (PDI, 
right-side axis). Error bars represent the standard deviation of 3 measurements. An asterisk (*, or **, or ***) depicts a statistically significant difference in 




Figure 3.16 Influence of storage time at 4°C on particle size and polydispersity of benzothiazinone-loaded human serum albumin nanoparticles 
manufactured by method I. The bars depict the hydrodynamic diameter (nm, left side axis) of particles and the lines depict the polydispersity index (PDI, 
right-side axis). Error bars represent the standard deviation of 3 measurements. An asterisk (*, or **, or ***) depicts a statistically significant difference in 




Figure 3.17 Influence of storage time at 25°C on particle size and polydispersity of benzothiazinone-loaded human serum albumin nanoparticles 
manufactured by method II. The bars depict the hydrodynamic diameter (nm, left side axis) of particles and the lines depict the polydispersity index (PDI, 
right-side axis). Error bars represent the standard deviation of 3 measurements. An asterisk (*, or **, or ***) depicts a statistically significant difference in 




Figure 3.18 Influence of storage time at 4°C on particle size and polydispersity of benzothiazinone-loaded human serum albumin nanoparticles 
manufactured by method II. The bars depict the hydrodynamic diameter (nm, left side axis) of particles and the lines depict the polydispersity index (PDI, 
right-side axis. Error bars represent the standard deviation of 3 measurements. An asterisk (*, or **, or ***) depicts a statistically significant difference in 




3.4.7 Benzothiazinone release studies 
BTZ release profiles from HSA nanoparticles prepared using both methods were 
performed over 48 h with and without the addition of 0.1 mg/mL trypsin (Figure 3.19).  IR 
20- and FG 2- loaded HSA nanoparticles were selected as representative BTZ formulations. 
In the absence of trypsin, BTZ release after 48 h was <10% and HSA nanoparticles 
prepared by Method I showed a marginal, but significantly higher cumulative BTZ release 
(%) at 48 h (Table 3.7). The presence of trypsin caused a rapid release of both BTZ 
compounds within the first 4 hours of incubation followed by a slower, steadier release 
rate over the subsequent incubation period. At the 48 h time point, ~88% and ~60% free 
IR 20 and FG 2 were released into the receiver medium.  Due to the higher loading 
efficiency achieved with Method II, the mass of free FG 2 released was significantly higher 
for nanoparticles prepared by Method II compared to Method I (Table 3.7). Similarity 
factors (f2) were greater than 50 for all comparisons, indicating that the preparation 
method does not have a substantial influence on release rate. Dissolution modelling 
showed IR 20 release for both methods in the presence of trypsin followed Logistic model 
kinetics (R2 = 0.988) whereas FG 2 release for both methods followed Weibull release 
kinetics (R2 = 0.975). 
Table 3.7 Comparison of cumulative percentage and mass of BTZ released from HSA 
nanoparticles prepared by Methods I and II over 48 h, both in the presence and absence of 
trypsin. f2 similarity factors >50 indicate that the compared release curves have on 
average <10% difference at each time point. Data represent the mean ± standard deviation 
of n=3 nanoparticle batches. * P<0.05, ** P<0.01, *** P<0.001 (comparison Method I vs II). 
 
Trypsin (-) Trypsin (+) 
  t = 48 h          
BTZ (%)  
t = 48 h          




  t = 48 h          
BTZ (%)  
t = 48 h          









IR 20 (I) 86.7 ± 
3.1 










FG 2 (I) 4.1 ± 
0.2*** 
0.8 ± 0.1 
90 
FG 2 (I) 60.7 ± 
2.1 
11.2 ± 1.2 
81 
FG 2 (II) 2.9 ± 0.2 1.5 ± 
0.2*** 








Figure 3.19 Cumulative BTZ release from HSA nanoparticles with and without the addition 





3.4.8 Antimycobacterial activity of IR 20 and FG 2 formulations 
The inhibition of intracellular Mycobacterium tuberculosis growth following macrophage 
infection was investigated over 72 hours of exposure to IR 20 or FG 2 formulations. IR 20 
and FG 2 were dissolved in DMSO and diluted in cell culture medium (Figure 3.20 A,B), 
presented in an HSA solution (Figure 3.20  C,D) or-loaded into HSA nanoparticles (Figure 
3.20 E,F).  Different concentration ranges were used for each drug based on differences in 
the MIC values: 3, 10, 100 µM for IR 20 and 0.3, 3, 10 µM for FG 2. The colony forming units 
(CFU) per mL on days 1, 2 and 3 of incubation with the formulations or BTZ-free vehicle 
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controls are presented in Figure 3.20, with the lower and upper dotted lines representing 
the mean CFU /mL values of untreated Mycobacterium tuberculosis-infected macrophages 
on day 1 and 3, respectively. 
 
As expected, FG 2 activity was greater than IR 20 activity for all formulations, reflecting 
the respective MIC values of the compounds.  Interestingly, the formulation strategy had a 
major impact on antimycobacterial efficacy of both compounds. BTZs encapsulated in HSA 
nanoparticles significantly reduced M. tuberculosis burdens compared to corresponding 
formulations in DMSO and HSA solution at all concentrations and timepoints tested 
(P<0.01), thus rendering the BTZs more effective, especially at the lower drug 
concentrations of 3 μM. The vehicles themselves had no impact on M. tuberculosis growth, 
with the exception of the HSA solution, which unexpectedly slowed bacterial growth over 




Figure 3.20 The antimycobacterial activity of three formulations of IR 20 (3, 10, 100 μM) 
and FG 2 (0.3, 3, 10 μM), in DMSO (A,B), HSA solution (C,D) or HSA nanoparticles (E,F). 
Graphs depict the total CFU/mL M. tuberculosis surviving drug treatment over an 
incubation period of three days.  Bacterial survival was also measured for vehicle controls 
(open symbols) containing equivalent amounts of DMSO, soluble albumin or unloaded 
albumin nanoparticles. The dotted lines in each graph represent the mean CFU/mL M. 
tuberculosis counted in untreated infected macrophages on day 1 (lower line) and day 3 
(upper line).  The mean ± standard deviation of values from three different experiments 
are reported.  * P<0.05, ** P<0.01, *** P<0.001 (Student t-test of vehicle vs. drug-loaded 





The aim of this study was to investigate the potential of human serum albumin (HSA) as a 
solution and as a nanocarrier for delivering antimycobacterial benzothiazinone (BTZ) 
compounds to the lungs. More specifically, the loading, release and antimycobacterial 
activity of four novel BTZ compounds were investigated. BTZs target mycobacterial-
infected alveolar macrophages- a well-documented target of nanoparticulate drug carriers 
(Hoagland et al. 2016; Nasiruddin et al. 2017; Costa-gouveia & Brodin 2017; Kaur & Singh 
2014; Costa et al. 2016; Mehanna et al. 2014; Sosnik et al. 2010; Andrade et al. 2013; 
Ranjita et al. 2011; Jawahar & Reddy 2012). Nanoparticles of the lipid, polymeric and 
inorganic variety have been investigated for TB treatment strategies however albumin-
based systems have been largely overlooked. Ahmad et al. developed a bovine serum 
albumin-based system loaded with levofloxacin (Rather et al. 2016), however 
antimycobacterial efficacy was not tested. Thus, it became important to comprehensively 
evaluate the anti-mycobacterial efficacy of the BTZ-loaded HSA nanoparticles in this study.  
 
To assess the suitability of albumin as a solubilising agent and carrier system for the BTZs, 
solubilisation studies and tryptophan quenching studies were used; the latter in particular 
as a rapid method for approximating BTZ binding strength to HSA. Solubilisation studies 
indicated HSA could increase the solubility of the BTZ compounds (2-fold for IR 20, 6-fold 
for IF 274 and over 100-fold for FG 2 and AR 112). However, these values were only 
obtained upon optimisation of the experiment via forming a BTZ film prior to incubation 
with HSA. This modification was carried out to determine whether an increase in drug 
surface area would increase the extent of BTZ solubilisation. As hypothesized 
solubilisation increased, particularly for the more hydrophobic FG 2 and AR 112 
compounds as noted above. Hence it can be deduced that dissolving the BTZ compound 
and forming a film prior to exposure to HSA provides a sufficient increase in surface area 
for the maximum increase in solubilisation by HSA. Despite the solubilisation of AR 112 
not being significantly different to the control, its low degree of solubilisation is mitigated 
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due to its very high potency. BTZ occupation of Sudlow’s site followed the trend of 
compounds solubility (IR 20 > IF 274 > FG 2 > AR 112). Drug binding studies with HSA as a 
plasma protein are extensively carried out because the binding affects the free, active 
concentration of the drug and the overall pharmacological profile of the drug e.g. drug 
disposition, elimination and efficacy. The importance of these studies also applies to the 
work carried out here with the use of albumin for drug delivery as one of the major 
questions relating to albumin as a carrier is whether lipophilic compounds are able to 
dissociate from albumin binding sites within a therapeutically relevant timeframe 
following administration. It was established that BTZs did not bind as strongly as 
endogenous compounds such as bilirubin, which suggested dissociation may occur more 
readily for the BTZs tested.  
 
Initially, BTZ compounds were incubated with HSA prior to manufacture of nanoparticles. 
Assessment of the loading of the BTZs showed good loading for IR 20 and IF 274 however 
poorer loading of FG 2 and AR 112 (as expected from solubilisation studies). As an attempt 
to improve this loading, an in-situ drug loading method (method II) was developed. This 
method particularly improved the loading for the more hydrophobic FG 2 and AR 112. 
This suggests method II is a suitable option for particularly hydrophobic drug compounds, 
whereas for less hydrophobic compounds such as IR 20 method I would still be a suitable 
option. The drug loading observed for the nanoparticles in these studies was comparable 
to other studies with albumin nanoparticles. Merodio et al. reported a loading of 14-26 
µg/mg albumin for ganciclovir-loaded albumin nanoparticles (Merodio et al. 2000), while 
a loading of between 1 and 16 µg/mg was reported by Arnedo et al 2002 for a 
phosphodiester oligonucleotide (Arnedo et al. 2002).  
 
The concerns regarding the ability of BTZs to dissociate from albumin nanoparticles in a 
therapeutically relevant time-frame were alleviated from the drug release studies. 
Diffusion of both IR 20 and FG 2 from albumin nanoparticles to albumin-containing 
88 
 
receiving fluid was observed over 48 h. What was interesting to note was the impact of 
protease on BTZ release from the nanoparticles, especially in the early time points (up to 4 
hours). As these are novel compounds, it is difficult to compare the drug release to existing 
studies. However, the release of existing anti-TB drugs from nanoparticulate systems have 
been studied previously. A study by Sung et al. studied the release of rifampicin from PLGA 
nanoparticles in vitro where an initial rapid release of drug was observed. They also 
looked at rifampicin levels in guinea pigs after inhaled administration of the drug-loaded 
nanoparticle formulations compared to nanoparticle-free formulations and found 
rifampicin presence in the lung for up to eight hours for the nanoparticle formulations, 
while the nanoparticle-free formulations had very short retention for rifampicin  (Sung et 
al. 2009). While the PLGA nanoparticles developed in this study were shown to sustain 
drug levels for longer, the drug-loaded albumin nanoparticles in this work appear more 
stable in PBS, with drug release occurring in the presence in enzyme and over a longer 
period. Furthermore, although PLGA is an FDA-approved excipient (Makadia & Siegel 
2011), there are concerns regarding the variable cytotoxicity and inflammation in 
response to modified-PLGA nanoparticles (Grabowski et al. 2013). The advancement of 
polymeric nanoparticle-based formulations for inhalation to treat tuberculosis depends on 
a greater understanding of the fate of the nanoparticles i.e. their breakdown, toxicity of 
polymeric constituents and activity against the infection (Gelperina et al. 2005).  
 
Regarding drug-loaded albumin nanoparticles that have been previously studied for 
alternative routes of administration, the drug release efficiency varies greatly. Das et al. 
report a drug release of 90% after 72 hours from aspirin loaded nanoparticles under 
physiological conditions (Das et al. 2005) and Merodio et al. found that 60% of the initially 
loaded drug was release from their most efficient nanoparticle for up to 5 days (Merodio 
et al. 2000), whereas Lin et al. only found a minimal release of less than 18% from their 
surface-modified albumin nanoparticles after 8 hours under physiological conditions. The 
drug release from those nanoparticles was increased to >90% in the presence of trypsin 
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(Lin et al. 2001). Interestingly, trypsin did not show an effect on the release profile in the 
experiments of Merodio and colleagues (Merodio et al. 2000). Furthermore, a positive 
correlation between drug release and increasingly acidic or basic pH was reported, likely 
due to the degradation of the nanoparticle (Battogtokh et al. 2018; Merodio et al. 2000; Lin 
et al. 2001). The different release behaviours observed for drug-loaded albumin 
nanoparticle systems stresses the importance of understanding drug-albumin 
interactions, loading mechanisms and subsequent activity of the systems.  
 
The antimycobacterial activity of the BTZ-loaded albumin nanoparticles was assessed in a 
TB-infected macrophage model. These experiments demonstrated that IR 20 and FG 2 
delivered by albumin vehicles within 24 hours in therapeutically relevant concentrations. 
Arguably the most important finding from this study was the impact the BTZ-nanoparticle 
formulation had on antimycobacterial activity. This can be explained by the ability of 
albumin nanoparticles to deliver drug to the macrophages more effectively, presumably by 
the preferential uptake of nanoparticles, followed by liberation of drug although this 
requires confirmation from mechanistic studies and the effect needs to be demonstrated 






The successful encapsulation of BTZs with both soluble albumin and albumin 
nanoparticles show they are effective drug carrier strategies for compounds with poor 
aqueous solubility such as BTZs. The nanoformulations were shown to be stable over a 
period of six months, with minimal drug losses via washing and other formulation 
processes. Drug release could be triggered by the presence of endogenous proteases, as 
confirmed by antimycobacterial activity studies in an M. tuberculosis infected macrophage 
model where the nanoparticle formulations not only showed retained activity despite the 
presence of albumin in the formulation, but demonstrated enhanced activity compared to 
the drug in solution.  
 
The results of these studies indicate the suitability of albumin as a drug carrier- 
particularly for highly potent compounds. The development of nanoformulations for 
delivery by inhalation is an intricate process often limited by compound properties. Like 
BTZs, compounds should be highly potent and possess high affinity to the albumin carrier. 
In the next chapter, the ability of albumin to produce respirable powders will be 







Chapter 4 Development of spray-dried powders containing 




In Chapter 3 it was demonstrated that albumin nanoparticles could successfully 
encapsulate poorly soluble anti-TB compounds (BTZs), allow drug release in a 
pharmaceutically relevant model and exert a pharmacological effect in a therapeutically 
relevant in vitro model. Pulmonary delivery of albumin nanoparticles provides an 
opportunity to deliver otherwise “difficult-to-formulate” compounds like BTZs to their site 
of action in a controlled and sustained manner, resulting in the use of lower doses and 
reduced frequency of dosing.  The development of nanoformulations for inhalation 
therapy is a multifaceted process, requiring the formulation to exhibit excellent 
aerodynamic properties (such as good fine particle fraction (FPF) and emitted dose (ED) 
which is indicative of good powder dispersibility) to allow sufficient mass/dose of drug to 
deposit in the lungs.  
 
There are currently three main types of inhaler devices used for pulmonary drug delivery: 
nebulisers, metered dose inhalers (MDIs) and dry powder inhalers (DPIs), each are 
different and require different kinds of formulations (Bailey & Berkland 2009). Nebulisers 
have been around historically (since the 1800s) and have been used to deliver solutions of 
drugs using air-jet or ultrasonic technology to generate aerosol droplets (Sung et al. 2007). 
There is also a variety of nebuliser that uses a vibrating mesh technology which is 
described in Chapter 1. Nebulisers are known to be bulky and not as portable as MDIs and 
DPIs, however this is now expected to change with the introduction of new “smart” 
nebulizer technologies (Pritchard et al. 2018). The small size of nanoparticle systems 
appear to make them suited for use with nebulisers, however particle agglomeration and 
stability is often an issue for these systems and the nanoparticle characteristics can 
influence particle aggregation during aerosolisation (Dailey et al. 2003). MDIs typically 
consist of drug dissolved or suspended in a liquid propellant such as HFA, and a metered 
dose is released upon actuation although these typically require co-ordination which 
makes them difficult to use (Bailey & Berkland 2009). MDIs containing suspensions 
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usually contain surface-acting agents which may impact lung performance (such as 
surfactants) (Siddiqui & Plosker 2005). The shortcomings of nebulisers and MDIs urged 
the development of an alternative delivery device, the dry powder inhaler (DPI). DPIs offer 
the advantage of storing drug in a dry state, conferring long-term stability (Sung et al. 
2007).  
 
Spray-drying has a wide range of applications in the pharmaceutical industry (Broadhead 
et al. 1992). This technique allows the modification of many parameters (such as inlet 
temperature, air pressure etc.) which allows optimisation of particle characteristics such 
as size, shape and dispersibility (Lee et al. 2011). When nanoparticles are involved in 
spray-drying processes, they are often prepared separately and then formulated as a 
dispersion where they will essentially be part of a larger microparticle, but still retain 
their favourable properties such as targeting or enhanced solubility (Vehring 2008; Yang, 
Peters, et al. 2008). These systems can become quite complex, especially when more than 
one solid dispersed phase is involved as is demonstrated in one example in a study where 
calcium salts were dispersed in an aqueous polymeric suspension and then spray dried to 
produce microencapsulated particles (Oneda & Ré 2003). 
 
There are many more complex examples in which this process has been studied in order 
to produce nanoparticle-containing microparticles suitable for inhalation (Raffin 
Pohlmann et al. 2002; Beck et al. 2006; Schaffazick et al. 2006; Tewa-Tagne et al. 2006). 
The vast array of modified techniques and processes that have been developed (wet 
milling, supercritical fluid extraction, electro-spray, high-pressure homogenisation and 
recrystallisation via solvent displacement for example) demonstrate the ability to produce 
nanoparticles with a high degree of control over particle properties (Bailey & Berkland 
2009). However, there are still limitations relating to drug loading, reproducibility in 




The reason why nanoparticles are often formulated as part of a larger microparticle is 
because the optimal particle size for achieving delivery to the deep lung is 1-5 µm, while 
the small size of nanoparticles would likely result in exhalation (Bailey & Berkland 2009). 
The choice of excipient is particularly important with nanoparticle formulations as the 
carrier will influence the powder aerodynamic properties and subsequent activity of the 
drug (Pilcer & Amighi 2010). It is desirable to work with excipients that are approved as 
safe due to the limitations posed by working with non-approved excipients such as the 
likelihood of extra work and the possibility of rejection from regulatory bodies (Pilcer & 
Amighi 2010). 
 
The dry powder formulations are usually preferred to the liquid counterparts (MDIs and 
nebulisers) because they have been shown to have the best stability properties and 
improved nanoparticle handling (Al-Qadi et al. 2012).  This is particularly advantageous 
for this work with albumin nanoparticles, as particular care needs to be taken with the 
chemical and physical stability of protein-based formulations during processing (Maa et al. 
1998).  
 
The use of albumin nanoparticle conjugates for drug delivery is well-documented in the 
literature for intravenous and intravitreal routes of administration (Wartlick et al. 2004; 
Zhao et al. 2010; Merodio et al. 2000; Lin et al. 2001; Chen et al. 2008). The pulmonary 
route is less documented and although spray-drying of albumin at first thought may seem 
a challenge due to the high temperatures normally employed during the manufacturing 
process, bovine serum albumin has been spray-dried previously. Papay et al. (Pápay et al. 
2017) prepared dry powders of apiginen-BSA conjugated nanoparticles in a manner 
similar to a study whereby high-pressure homogenisation was employed to produce 
nanosized drug-albumin conjugates in which albumin acts as a stabiliser for the nanosized 
drug particles (Chen et al. 2008). In these studies, the albumin nanoparticles are not the 
drug carrier themselves, rather they act as a scaffold for the drug in nanoparticulate form. 
95 
 
This is a different concept to the aim of this work. The purpose of this work is to utilise 
albumin nanoparticles as a drug carrier and preserve this in an inhalable formulation for 
delivery to the lung.  This would allow the albumin nanoparticles themselves to dictate the 
drug release behaviour and subsequent pharmacological activity.  
 
Therefore, the aim of the work in this Chapter was to develop a respirable dry powder 
formulation for delivery of albumin nanoparticles as an inhalable aerosol. The following 
were the specific objectives of this work: 
- Design a formulation and manufacturing method for spray-drying based on 
commonly used excipients 
- Characterise the powders in terms of yield, particle size distribution, 
redispersibility, aerosol performance and surface morphology 
- Optimise the inhalable formulation in terms of nanoparticle loading and 
aerodynamic performance in preparation for incorporation of a model drug 
A heuristic approach was employed to select a formulation platform to develop further 





Mannitol, trehalose, leucine and human serum albumin (HSA) (low endotoxin, fatty acid 
free) was purchased from Sigma-Aldrich (Dorset, UK). All solvents were of HPLC grade 





4.3.1 Formulation strategy 
Prior to spray-drying, excipients were chosen to form matrix formulations. Mannitol was 
selected as it is a popular excipient for spray-drying. A second system with trehalose and 
leucine was selected for comparison. 
 
4.3.2 Spray-drying 
Formulations were spray-dried using a laboratory scale, customised co-current spray 
dryer (Vectura spray dryer, Vectura Ltd.) with a two-fluid nozzle. Table 4.1 shows the 
operating conditions for spray-drying.  The solution was pumped into the spray-dryer and 
the resultant powder was separated from the airstream using a cyclone separator. The 
powder was collected in a container.  
 
Table 4.1 Operating conditions used for spray-drying in this study 
Conditions  
Feed concentration (% w/v) 4 
Inlet temperature (°C) 106 
Outlet temperature (°C) 65 
Feed rate (mL/min) 2.0 
Atomisation flow (L/min) 17 
Atomisation pressure (bar) 2.5 
Drying air flow (kg/h) 17 
Drying air pressure (bar) 2.5 
 
For the preparation of albumin nanoparticle-containing microparticles, albumin 
nanoparticle suspensions were prepared as described in Chapter 2. For initial experiments 
with mannitol and trehalose/leucine matrix production, nanoparticle suspensions were 
purified in saline. For subsequent experiments following the selection of mannitol as an 
appropriate matrix for the albumin nanoparticles, nanoparticle suspensions were purified 
in water. All preparation mixtures contained a total solids content of 4%, and albumin 
nanoparticles made up 20% of the total solids. To prepare albumin nanoparticles in a 
mannitol matrix, albumin nanoparticles (200 mg) and mannitol (800 mg) were made up to 
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25 mL with water. To prepare albumin nanoparticles in trehalose/leucine matrix, albumin 
nanoparticles (200 mg), trehalose (600 mg) and leucine (200 mg) were made up to 25 mL 
with water. Controls consisted of 1g mannitol in saline/water (25 mL) and trehalose (800 
mg)/leucine (200 mg) in saline (25 mL). The saline was included to mimic the saline 
content in the nanoparticle suspensions. The preparation mixtures were fed into the 
spray-dryer using a peristaltic pump. The spray-dried powders were recovered, weighed 
and stored at room temperature in a desiccator. Sample yields were determined by 
weighing the recovered powder and dividing the value by the initial mass of solids present 
in the feed stock.   
 
Further spray-drying studies were carried out with albumin nanoparticles in a mannitol 
matrix at varying nanoparticle concentrations (20%, 30%, 40% and 50%). These 
nanoparticle particle suspensions were purified in water and spray-dried using the same 
conditions as described above. 
 
4.3.3 Particle Size Distribution (PSD) 
Powder size distribution (D90, D50 and D10) was measured using laser diffraction 
(Mastersizer 3000, Malvern Instruments, UK). The sample was dispersed in in 2-2-4 
trimethyl pentane and sonicated at 50% intensity for 3 mins using a sonic probe [Sonopuls 
HD3100 (Bandelin, Germany)].  
 
4.3.4 Reconstitution and dynamic light scattering (DLS) 
Reconstitution of the spray-dried powder was carried out by dispersing 10 mg of the 
powder in distilled water (2 mL). After centrifugation at 2000 g for 10 min, 1.5 mL 
supernatant was removed and the presence of any nanoparticles was determined by 
dynamic light scattering (Zetasizer nano ZSP, Malvern Instruments, UK). The samples 




4.3.5 Nanoparticle recovery and uniformity content 
Albumin nanoparticle recovery was determined by dissolving 50 mg of the spray-dried 
powder in water (10 mL). Nanoparticles were separated from the resulting mixture by 
centrifugation with centrifugal filters (MWCO 100 kDa; Amicon Ultra). Nanoparticle 
recovery yield (%) was determined gravimetrically. 
 
4.3.6 Fast Screening Impactor (FSI) studies 
Aerosol performance of spray dried formulations were assessed using a Fast Screening 
Impactor (FSI, Copley Scientific, UK) with a 5 µm cut point insert. Hand-filled sealed 
aluminium blisters containing 10 ± 0.5 mg spray dried powder were dispersed at 60 
L/min for 4 seconds using a unit dose dry powder inhaler (Vectura Ltd, UK). Fine particle 
fraction (FPF % ≤ 5 µm) and blister evacuation (% fill mass) were determined 
gravimetrically (n=3 per formulation). 
 
4.3.7 Scanning electron microscopy (SEM) 
SEM images were kindly taken by Ursula Potter and Diana Lednitzky [Bath University 
(UK)]. Powder samples were sprinkled onto double sided carbon tabs and sputter coated 
with gold for 3 minutes. Samples were imaged using a JEOL JSM-6480LV tungsten filament 
scanning electron microscope in high vacuum mode. Images were taken at 100, 1,000, 






4.4.1 Spray-dried microparticle characteristics 
Incorporating nanoparticles into the formulations had no effect on the size of powders 
produced (Table 4.2). The control formulations contained saline to mimic saline content in 
original nanoparticle suspensions. Due to the larger D50 and D90 values for mannitol in 
saline (3.24 µm and 8.06 µm, respectively) saline was omitted from the matrix formulation 
. Henceforth mannitol was spray-dried in water only, resulting in D50 and D90 values of 2.78 
µm and 4.84 µm, respectively which was comparable to the other powder batches. The 
recovery yields were similar for both trehalose/leucine batches with and without 
nanoparticles, however the incorporation of nanoparticles with mannitol resulted in a 
yield reduction from 73.6% to 40.8%. 
 
Table 4.2 Particle size and yield of spray-dried formulations: mannitol in saline; trehalose 
(trehalose: leucine 80:20 in saline); mannitol in water only; nanoparticles suspended in 
saline (20% of total solids content) in a mannitol in water matrix, and finally albumin 
nanoparticles suspended in saline (20% of total solids content) in a trehalose/leucine in 
water matrix. Results are from single powder batches. Total solids content for all 
formulations was 4%.   
Formulation matrix Nanoparticles? D10 D50 D90 
Yield 
(%) 
Mannitol in saline No 1.05 3.24 8.06 82.0 
Trehalose and leucine in 
saline 
No 1.12 2.43 4.65 56.2 
Mannitol in water No 0.92 2.78 4.84 73.6 
Mannitol in water Yes 0.96 2.50 4.82 40.8 
Trehalose and leucine in 
water 





4.4.2 Nanoparticle recovery from dry powders upon aqueous reconstitution 
The microparticles swiftly dissolved when dispersed in aqueous solution. The size and PDI 
of nanoparticles recovered after dissolution as well as the size and PDI of the original 
nanoparticle suspensions are shown in Table 4.3. All nanoparticle sizes were similar to the 
original size (± 10%). Nanoparticle recovery for both the mannitol and trehalose/leucine 
systems was 95% & 75%, respectively. 
 
Table 4.3 Nanoparticle size before spray-drying and after reconstitution of dry powder 
and nanoparticle recovery. Data is from a single powder batch.  
Formulation Size before 
spray-drying 
(nm) & [P.D.I.] 
Size (nm) & 
[P.D.I.] after 
reconstitution 
Percentage (%) of 
nanoparticles in 50 mg 
powder &  recovery [%] 
Mannitol 123.8 [0.059] 133.2 [0.023] 19.0 [95] 
Trehalose/leucine 120.6 [0.042] 108.0 [0.060] 15.0 [75] 
 
 
4.4.3 Fine Particle Fraction (FPF) evaluation of dry powders 
Blister evacuation for all spray-dried powders was > 95% (Table 4.4). Trehalose/leucine 
systems both with and without nanoparticles had higher fine particle fractions (68.0 & 
60.6% respectively) compared to mannitol systems (30.4% & 39.3%).  
 
Table 4.4 Fine Particle Fraction (FPF) and blister evacuation (%) of dry powders screened 
by Fast Screening Impactor (FSI). Values reported are derived from a single powder batch 
with the mean and standard deviation of n = 3 blisters. 
Formulation Blister evacuation (%) FPF (%) 
Mannitol control 95.4 ± 4.4 39.3 ± 3.3 
Trehalose/leucine control 100.8 ± 5.3 60.6 ± 2.9 
Albumin nanoparticles in mannitol 96.5 ± 1.2 30.4 ± 5 





4.4.4 Effect of nanoparticle concentration on dry powder characteristics 
Mannitol was selected as the most appropriate excipient for formulations of the albumin 
nanoparticles into a dry powder. All albumin nanoparticle-containing dry powder 
formulations had a nanoparticle content of 20% (out of total solids). Increasing 
nanoparticle content would allow maximum drug content in final powders. The effect of 
increasing albumin nanoparticle content on the characteristics of dry powders produced 
was studied. Albumin nanoparticles in water embedded in a mannitol matrix were spray-
dried at 20-50% content and assessed for aerodynamic properties (Table 4.5). Powders 
were produced with batch yields of 68-71%. There were no significant changes to 
nanoparticle sizes after reconstitution (Table 4.5). Laser diffraction revealed D50 values 
(geometric diameter) were in the size range 1-5 µm which is the optimum size range as it 
is well documented particles within this size range achieve “deep lung deposition” (Bailey 
& Berkland 2009; Shi et al. 2007). The D50 increased from 2.2 to 2.7 µm with increasing 
nanoparticle content. FPF (%) decreased with increasing albumin nanoparticle content, 
with values of 49.9% and 17.0% for powders containing 20% and 50% albumin 
nanoparticle content, respectively (Figure 4.1). Changes in nanoparticle content had no 






Table 4.5 Properties and aerodynamic performance of spray-dried powders composed of 20-50% (w/w) HSA nanoparticles embedded in a mannitol 
matrix.  Values reported are derived from a single powder batch.  





D10 D50 D90   
20% (w/w)  68 120 119 0.92 2.24 5.07 94.4 49.9 
30% (w/w) 71 169 167 1.01 2.42 5.42 95.8 39.6 
40% (w/w) 69 165 162 1.03 2.49 6.15 98.2 34.7 




Figure 4.1 Illustration depicting the effect of albumin nanoparticle concentration in spray-
dried powders embedded in a mannitol matrix on D50 (µm, left-side axis) and Fine Particle 
Fraction (%, right-side axis) as determined through Fast Screening Impactor (FSI) studies.  





















Figure 4.2 Representative scanning electron micrographs of spray-dried powders. .  
Images represent powders containing 0%, 20%, 30%, 40% and 50% albumin nanoparticle 





The suitability of albumin nanoparticles as drug carriers was previously demonstrated in 
Chapter 3. The natural next step for their development as an inhalable formulation is to 
manufacture a respirable albumin nanoparticulate formulation for delivery via inhalation. 
Therefore, in this chapter the development of spray-dried microparticles containing 
albumin nanoparticles was investigated.  
 
The selection of appropriate spray-drying excipients is important in determining how the 
produced microparticles behave, particularly in terms of disintegration time and 
subsequent release of contents as well as stability (Grenha et al. 2005; Kho & Hadinoto 
2010). A matrix-forming excipient is particularly important for nanoformulations as it 
forms bridges between nanoparticles during spray-drying to prevent them from 
agglomerating (Torge et al. 2017). The matrix in theory should dissolve in contact with 
liquid to release the nanoparticles. Mannitol is a popular matrix excipient for spray-drying 
due to its low toxicity and high aqueous solubility (Scherließ 2016; Grenha et al. 2005). 
Trehalose is another suitable cryoprotectant often used, its water solubility is much higher 
than mannitol, predicting good re-dispersibility of powders. However, it has been shown 
that although spray-drying with trehalose prevents aggregation and produces smaller 
particles, a larger fraction of these particles is left behind in the spray-drying chamber, 
resulting in low powder yields (Maury et al. 2005; Freitas & Müller 1998). Trehalose can 
sometimes also prove to be difficult to handle as a powder as it has been reported to form 
sticky aggregates when spray-dried at an inlet air-temperature of 90°C, suggesting it may 
be unsuitable on its own as an excipient for spray-drying (Adler & Lee 1999; Maa et al. 
1997). To prevent this, it was suggested leucine (a hydrophobic excipient) be used in 
combination with trehalose as a possible means to improve aerosolisation efficiency (Kho 
& Hadinoto 2010; Wang et al. 2012). Leucine has been used in spray-drying with a view to 
improve dispersion properties of substances in microparticles and protect against 
moisture upon aerosolisation (Najafabadi et al. 2004; Li et al. 2016). It is among many 
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amino acids that have been shown to decrease hygroscopicity and improve the in vitro 
deposition profile of spray-dried powder formulations (Seville et al. 2007). In studies with 
various amino acids, leucine has been shown to be the best in terms of aerosolisation 
properties (Pilcer & Amighi 2010). Leucine, along with mannitol and trehalose is a 
“generally regarded as safe” (GRAS) excipient (Pilcer & Amighi 2010) and has a high glass 
transition temperature making it a suitable stabiliser of proteins (Adler & Lee 1999). The 
ratio of 1:4 leucine: trehalose was selected to ensure nanoparticle recovery from 
reconstitution of the powders.  
 
The initial powders produced in this work; apart from mannitol spray-dried in saline; had 
diameters of ~ 4µm which was considered suitable to achieve sufficient deposition in the 
lower airways (Bailey & Berkland 2009). However, it should be noted that particle sizes 
discussed in this work are geometric particle sizes (which is measured by light 
diffraction). The aerodynamic diameter (daer) is related to the geometric diameter 
(assuming particles are spherical) by the Equation 4.1, where d is geometric diameter 
(nm) and p is particle density normalised by the density of water (1 g/cm3) (Tsapis et al. 
2002).  
Equation 4.1 
         
It is widely accepted that particles of aerodynamic diameter of 1-5 µm are optimal for 
middle-deep lung deposition (Shekunov et al. 2007), however in reality the effective 
aerodynamic diameter depends on many factors such as shape, surface morphology and 
flow geometry (Shekunov et al. 2007). The particle density of the powders developed in 
this work was not evaluated, however PSD remains a major parameter that influences 
powder deposition in the lung and should be evaluated (Shekunov et al. 2007). 
 
Spray-drying mannitol in saline increased the size of powders produced. However, the 
inclusion of saline in trehalose/leucine systems did not have this effect. It is not 
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understood why saline may have had this effect on the mannitol matrix system. 
Subsequent nanoparticle suspensions were free of saline and purified in water in a buffer 
exchange. 
  
Albumin nanoparticles withstand spray-drying conditions despite concerns the high 
temperatures may adversely affect nanoparticle structure. Regardless of using a high inlet 
temperature of 106°C, a low outlet temperature of 65°C was maintained. These 
temperatures are favourable for the spray-drying of heat sensitive substances like 
proteins (Lee et al. 2011). The initial selected spray-drying conditions were kept the same 
throughout all the studies and were not experimentally optimised because powder 
characteristics were generally considered to have properties deemed within the range 
that was aimed for with this work (such as yield and particle size).  Nanoparticle recovery 
and uniformity was good, with some nanoparticle loss being attributed to the spray-drying 
process. Redispersibility of the powders was assessed in a simplified model with a small 
volume of aqueous solution to mimic the small volume of fluid found in the human lung 
(estimated to be between 15 and 70 mL (Patton 1996). Despite this similarity, there may 
be other factors that need to be taken into consideration to more accurately represent in 
vivo behaviour. Ruge et al. studied the disintegration of nano-embedded microparticles on 
a mucus layer as an attempt to address this and found that disintegration did not occur on 
a static mucus layer but did occur with mechanical stirring of the mucus phase (Ruge et al. 
2016). However, mucus models are limited in terms of comparability with biological 
mucus and are very complex, particularly for use with nanoparticle formulations (Torge et 
al. 2017). Some studies have used simulated lung fluid to assess the release of 
nanoparticles from spray-dried formulations (Debnath et al. 2017; Sinha et al. 2013; 
Rosière et al. 2015). It may be useful to explore other relevant models for future in vitro 




Despite the improved FPF (%) in trehalose/leucine systems and slightly better yields, 
after working with both excipient systems, mannitol was selected for further experiments 
due to its ease of handling (lower susceptibility to moisture) and predictability. Naini et al. 
found mannitol to be apparently 100% crystalline upon spray-drying, with no humidity-
induced changes (Naini et al. 1998). Spray-dried nanoparticle-containing microparticles 
with mannitol as an excipient have been produced in studies with acceptable aerodynamic 
properties for delivery to the lung (Grenha et al. 2007; Kho & Hadinoto 2010). Mannitol 
readily dissolves in water and so it was theorised after delivering spray-dried albumin 
nanoparticles in a mannitol matrix to the lung, the mannitol matrix would dissolve rapidly 
on the epithelial surface, leaving behind the nanoparticles to release drug and thereafter 
exert its therapeutic effect. The notion of allowing the drug-nanoparticle interactions to 
predominantly dictate release kinetics, as opposed to the excipient makes mannitol more 
favourable as leucine may potentially retard drug release in the lung due to its 
hydrophobicity and subsequent poor aqueous solubility (Wang et al. 2012). The 
trehalose/leucine systems had more favourable yields, however, when additional albumin 
nanoparticles in water (no saline) were spray-dried with trehalose/leucine and compared 
to albumin nanoparticles spray-dried with mannitol, they were found to have a yield of 
60%, with the mannitol system achieving a yield of 67%. Furthermore, powders in the 
trehalose/leucine matrix were found to be “sticky” in nature, owing to the trehalose. It has 
been suggested that this stickiness can be overcome with the use of higher inlet 
temperatures, however for peptide/protein based products this may be counter-intuitive 
as thermal stress may cause protein deactivation (Adler & Lee 1999).  
 
Therefore, mannitol was selected for further experiments investigating the effect of 
increasing nanoparticle content, and for other further work. Mannitol does not carry any 
reducing groups and so it does not cause chemical interactions with drugs or proteins, and 
it is highly crystalline even upon spray drying, making it seem like an ideal excipient (Maas 
et al. 2011). Trehalose on the other hand tends to be amorphous and deemed 
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inappropriate at high concentrations for aerosol applications due to its high degree of 
agglomeration, likely resulting in poor redispersibility (Maa et al. 1997), although it was 
originally considered for this work because in its amorphous state it stabilises proteins. It 
has been said that trehalose sorbs water and then crystallises and phase separates from 
the protein, acting as a dessicant  (Moran & Buckton 2009). Variability in the crystalline 
behaviour of amorphous trehalose has also been reported, depending on the 
concentrations used during spray drying (Moran & Buckton 2007).   
 
With the successful encapsulation of nanoparticles in the mannitol matrix at 20% total 
solids content, the next step was to investigate the effect of increasing the nanoparticle 
content. Maximising albumin nanoparticle content in spray-dried formulations would 
potentially increase the amount of drug delivered to the lung. SEM micrographs (Figure 
4.2) showed spray-drying mannitol on its own and mannitol with 20% albumin 
nanoparticle content produced spherical particles with smooth surface.  Upon increasing 
the nanoparticle content, the surface of the particles has ridges and appear rough although 
the spherical shape is retained. Having 50% albumin nanoparticle content produced 
powders that were sticky, as indicated by the difference in blister evacuation. It also had a 
remarkably lower FPF (17% compared to 35% and 40% for formulations containing 40% 
and 30% albumin nanoparticle content). This could be due to increased poor particle 
disaggregation upon aerosolisation. This could be linked to the location of the 
nanoparticles within the matrix. The change in size and performance suggests the 
nanoparticles are likely to be located at the particle surface. Confocal laser scanning 
microscopy (CLSM) can be used to observe the spray-dried powder particles, staining the 
particles with fluorescent labels would make them easier to observe under the 
microscope. Examination of cross-sections through the carrier particles would provide 
information about the distribution of nanoparticles (Sham et al. 2004). The little difference 
between 30% and 40% albumin nanoparticle content formulations in appearance and 
aerosol performance indicates 40% as the optimal nanoparticle content for spray-drying. 
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The 40% formulation was selected as it appears to have the most potential for delivering 
the highest amount of nanoparticles (through FSI testing), thus providing the most 




In summary, these pilot studies demonstrate that incorporation of albumin nanoparticles 
into respirable carrier particles is possible. The spray-dried powders developed in this 
work had suitable size for lung deposition and albumin nanoparticles were recoverable 
after the spray-drying process with good re-dispersibility and uniformity. The spray-dried 
mannitol formulation with a nanoparticle content of 40% was selected as the most 
promising. Therefore, in the next chapter this formulation will be explored further with 












Chapter 5 Formulation and characterisation of respirable 




The work carried out in chapter 4 focused on the development and optimisation of a 
spray-dried formulation containing albumin nanoparticles. Albumin nanoparticles were 
able to survive the spray-drying process and the resulting formulated powders showed 
promising aerosolisation properties. In order to assess the clinical viability of the aerosol 
formulation, a model drug must be incorporated into the formulation and investigated for 
suitability for aerosol delivery. 
 
When spray-drying with nano-encapsulated drugs, carrier excipients are usually included 
in copious amounts which limits the amount of drug that can potentially be included in the 
formulation, therefore spray-drying in this case is normally suited to fairly potent drugs 
(Pilcer & Amighi 2010). Much like the BTZ compounds studied in chapter 3, drugs for 
formulation in this way i.e. encapsulated drugs, must not only be highly potent but should 
exhibit high encapsulation efficiencies and exhibit excellent aerodynamic properties.  
 
The BTZs studied in Chapter 3 of this thesis were not available for spray-drying studies, 
therefore an alternative model drug, roflumilast, was proposed. Roflumilast is a poorly 
soluble phosphodiesterase-4 (PDE4) inhibitor. It is used for maintenance of severe chronic 
pulmonary obstructive disease (COPD) as PDE4 is the main isoenzyme in lymphocyte cells 
involved in COPD. It is available in tablet form and administered as 250-500 µg daily 
(Hohlfeld et al. 2008). Unfortunately, oral roflumilast comes with some adverse effects 
such as insomnia, anxiety and depression which is more common in patients with body 
weight < 60 kg due to higher total PDE4 inhibitory activity (Electronic medicines 
compendium, 2018).  The pulmonary route of administration provides a potential avenue 
to minimise these adverse effects (Kuzmov & Minko 2015). In one study, inhaled 
roflumilast was administered intratracheally to Brown Norway rats and found the inhaled 
drug showed greater improvement in the lung function compared to oral roflumilast 
(Chapman et al. 2007).  Roflumilast is also known to have an anti-inflammatory effect, in 
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one study it was found to reduce tumour necrosis factor- α (TNF-α) levels in human lung 
macrophages (Buenestado et al. 2012). Another study by Murad et al, 2017 showed 
inhaled roflumilast decreased macrophage and neutrophil levels in the BAL fluid of 
BALB/c mice  (Murad et al. 2017). These studies report the investigation of inhaled 
roflumilast, however the literature lacks the application of roflumilast in a nanocarrier 
formulation.  There is one study that investigated the use of a cyclodextrin-based 
microcarrier for roflumilast for inhalation (Mahmoud et al. 2018). The use of an albumin 
nanocarrier formulation provides the advantage of the potential for controlled release 
over a longer period of time and higher potency (as demonstrated in Chapter 3 with the 
enhanced antimycobacterial activity of the BTZ-loaded albumin nanoparticle 
formulations). 
 
Dry powders can act as protectants for active compounds, protecting them from enzymatic 
degradation and allowing a more controlled release approach, reducing the amount and 
frequency of dosing (Panda et al. 2016). In the case of roflumilast, the reduction of adverse 
effects as well as improvement in delivery to the site of action (i.e. the lung itself) make it a 
suitable model drug for these studies. Direct delivery of drugs to the lungs via aerosol can 
enable the effective dose to be reduced up to 33-fold (Pandey et al. 2003). This means a 
dose of 6-12 micrograms of roflumilast in a capsule containing 10 mg powder for 
inhalation would be an adequate target dose (assuming a similar increase in clinical 
efficacy to that shown for inhaled salbutamol (200-800 micrograms vs. 4-16 mg orally) 
and for inhaled rifampicin (Pandey et al. 2003). 
 
Therefore, the aim of this work was to investigate whether roflumilast can be formulated 
with albumin nanoparticle carriers and loaded in respirable spray-dried powders. The 
specific objectives to aid in achieving this were set as follows: 
- study roflumilast-albumin interactions 
- produce albumin nanoparticles containing roflumilast 
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- spray-dry these using the optimised formulation in chapter 4 and characterise 
their aerosolisation capabilities.  






Mannitol was purchased from Sigma Aldrich, UK. Roflumilast was kindly provided by 





5.3.1 UV analysis of roflumilast 
A UV calibration curve was prepared for roflumilast and establishment of the limit of 
detection and quantification in methanol using UV spectrophotometry. To determine the 
absorbance maximum, a solution of roflumilast (30 μg/mL) in methanol was prepared and 
scanned over wavelengths 200-800 nm using the Perkin Elmer Lambda 2 UV/Vis 
spectrophotometer and a quartz cuvette (High precision cell, Hellma Analytics). A peak at 
248 nm was determined as a suitable wavelength for detection of roflumilast. A calibration 
curve of roflumilast in methanol was prepared using solutions within the range 100- 2 
μg/mL and taking a single absorbance value at 248 nm until readings within the range 1.0 
to 0.1 were obtained. LOD and LOQ was calculated using Equation 3.1 and Equation 3.2.  
 
5.3.2 Determination of roflumilast interactions with albumin by solubilisation 
Stock solutions of HSA (fatty acid-free, Sigma-Aldrich, Germany) in water and Tris buffer 
(50 mg/mL) were prepared. Negative controls consisted of water and Tris buffer without 
HSA.  HSA solutions and negative controls (1 mL) were added to separate vials containing 
1 mg roflumilast and incubated at 37°C for a total of three days. Samples of the 
supernatant were removed at pre-determined time points and UV absorbance readings in 
methanol were taken at 248 nm. The amount of drug dissolved by each solution was 
determined from the calibration curve and calculated as a percentage of the original drug 
content. 
 
5.3.3 Roflumilast binding to Sudlow’s site I via tryptophan quenching 
Roflumilast binding to the albumin drug binding site I, i.e. the hydrophobic pocket, was 
assessed through tryptophan quenching studies (Abou-Zied & Al-Lawatia 2011). HSA 
solution (1 mL, 1 µM) was prepared in 1:1 saline (25 mM) and Tris buffer (25 mM, pH 7.4).  
Stock solutions (1 mL, 500 µM) of roflumilast, ibuprofen (negative control) and bilirubin 
(positive control) were prepared in DMSO. The emission spectrum of HSA tryptophan 
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fluorescence was measured between 300 nm to 400 nm with an excitation wavelength of 
285 nm and an emission slit of 10 nm using a Perkin Elmer LS 50B Fluorescence 
spectrometer and a quartz cuvette (Hellma Analytics). Initial fluorescence readings were 
taken for the HSA solution, followed by subsequent readings after sequential additions of 
1 µL of drug. The maximum emission value (arbitrary units) of tryptophan fluorescence 
for each titration was divided by the emission value of HSA solution and results were 
presented as the percentage of tryptophan quenching versus drug concentration. 
 
5.3.4 Roflumilast-loaded albumin nanoparticle manufacture 
Roflumilast (1 mg) was weighed in a glass vial (vial I) and dissolved in ethanol (4 mL). HSA 
solution in Tris buffer (1 mL, 50 mg/mL) was prepared in a glass vial (vial II). After the 
addition of 25 µL NaOH to the HSA solution, the roflumilast solution was added drop wise 
to the stirred protein solution. Nanoparticles were then cross-linked and purified in the 
same manner as described in Chapter 3. The washing fluid was collected for roflumilast 
quantification (vial III). Roflumilast content in vials I-III was quantified and mass balance 
was calculated as described in Chapter 3. 
 
5.3.5 Physicochemical characterisation of nanoparticle suspensions 
The nanoparticle suspensions were characterised as described in chapter 3. 
 
5.3.6 Scaling up of nanoparticle suspensions for spray-drying studies 
For spray-drying studies, roflumilast (8 mg) was dissolved in ethanol (32mL) and added 
drop wise to HSA solution in tris buffer (8mL, 50 mg/mL) and cross-linked and 




5.3.7 Spray-drying of roflumilast-loaded albumin nanoparticle suspensions 
Roflumilast-loaded albumin nanoparticles in a mannitol matrix were produced by spray-
drying at a concentration of 40% and characterised for yield and FPF as described in 
Chapter 4. 
 
5.3.8 Drug content analysis of spray-dried powders 
Spray-dried powder (10 mg) was reconstituted with water. Roflumilast was extracted 
from the suspension with dichloromethane, in the same manner as Chapter 3. Methanol 
was added to roflumilast extracts and quantified by UV analysis. 
 
5.3.9 Roflumilast release studies 
Roflumilast release profiles in the nanoparticle suspensions was determined in the same 
way as described in chapter 3. Roflumilast release from the spray-dried powder 
formulations were determined by reconstituting 25 mg of spray-dried powder (equating 
to 10 mg of nanoparticles) in 1mL water. This mixture was then analysed in the same 
manner as for roflumilast nanoparticle suspensions. Similarity factor (f2) was calculated 
using Equation 3.7 to compare drug release profiles from roflumilast-loaded albumin 
nanoparticles and spray-dried powders containing roflumilast-loaded albumin 
nanoparticles with and without the presence of trypsin. Drug release data was analysed 
using several mathematical models to find the best kinetic model.   
 
5.3.10 Scanning electron microscopy (SEM) 
SEM analysis was carried out as described in Chapter 4. 
 
5.3.11 PreciseInhale® 
Dry powder aerosols were generated using the PreciseInhale® system (Inhalation 
Sciences, Sweden) which has been described previously (Lexmond et al. 2018; Selg et al. 
2013). Powder sample is loaded into the dosing chamber and then ejected by a high-
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pressure air jet through a nozzle into a holding chamber, where the aerosol is collected for 
analysis. The aerodynamic PSD of the aerosol was determined by cascade impaction 
analysis using a Marple Cascade Impactor attached to the exposure outlet with gravimetric 
measurements (Figure 5.1).   
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Table 5.1 shows the cut-off diameter for each impactor stage. The Multiple Path Model of 
Particle Dosimetry (MPPD) software was then used to calculate theoretical aerosol 
composite deposition in a human lung, as well as the normalised fractional distribution 
between the bronchi and alveoli. The assumptions/inputs for the human lung model were 
as follows: breathing rate 12 breaths per minute (BPM), upright position for breathing, 




Figure 5.1 The PreciseInhale® system. Here a Marple Cascade Impactor is attached to the 





Table 5.1 Diameter cut-off values (µm) for Marple Cascade Impactor stages 









End filter 0.25 
 
5.3.12 Statistical analysis  
Statistical analysis was carried out using SigmaPlot version 14.0 (SyStat software inc.). 
One-way ANOVA was carried out following by post-hoc tests when appropriate. P values < 






5.4.1 UV analysis of roflumilast 
Roflumilast was scanned over the UV range of the wavelength spectrum and 248 nm was 
deemed as a suitable wavelength. The calibration curve of roflumilast constructed in 
methanol showed the drug obeyed Beer-Lambert’s law over the concentration range 20-
100 µg/mL with a high correlation coefficient (R2 = 0.999) and regression equation Y = 
0.006x + 0.003 (Figure 5.2). The LOD was 1.56 µg/mL and the LOQ was 4.73 µg/mL. Inter-
day and intraday variation is shown in Table 3.2. The average intra and inter-day variation 
for roflumilast complied with the acceptance criteria proposed in analytical guidelines 












Table 5.2 Inter-day and Intra-day coefficients of variation (%) for different concentrations 
of roflumilast solution in methanol 
Concentration 
(µg/mL) 
Coefficient of variation (%) 
Intra-day Inter-day 
20 0.72 0.78 
40 3.42 1.69 
60 0.66 3.13 
80 1.70 2.08 
100 1.41 0.95 
 
 
5.4.2 Roflumilast-albumin solubilisation 
The temporal profile of roflumilast solubilisation by HSA was assessed over a three-day 
period (Figure 5.3). The solubility profile of roflumilast in Tris and HSA solutions was 
assessed to determine whether drug solubilisation by albumin can occur in a buffer 
solution at pH 8.9, as used to generate albumin nanoparticles. Roflumilast was not found 
to be soluble in tris buffer. Solubilisation in HSA was found to be ~13%, which 
corresponds to 2.6 µg drug per mg albumin. There was no significant increase in the 





Figure 5.3 Roflumilast time dependent solubilisation profile (1 mg) in 1mL HSA in tris 
buffer pH 8.9. Results are expressed as a percentage of the original mass (500 µg) at t=0. 
Results reported are from n=3 experiments.  
  
 
5.4.3 Roflumilast binding to Sudlow’s site I 
The importance of assessing a drug’s interactions with the binding sites of albumin have 
been exemplified in Chapter 3. In short, characterisation of the binding of roflumilast to 
drug binding site I (or Sudlow’s site I) of the albumin molecule may determine the 
effectiveness of HSA as a carrier for roflumilast, and subsequent nanoparticle and dry 
powder formulation.  
 
When a drug binds to binding site I, it lowers the overall intrinsic fluorescence of the 
albumin molecule. Thus, characterising this change in fluorescence gives an indication of a 
drug’s affinity for the binding site. Compared with ibuprofen, which does not bind to site I, 
and bilirubin, which shows a strong affinity to site I, roflumilast showed a weak affinity to 
the hydrophobic binding site of albumin (Figure 5.4). This affinity can be compared to the 
previously investigated BTZ compounds in Chapter 3. Despite the low to moderate affinity 





Figure 5.4 Quenching of tryptophan fluorescence indicating the strength of roflumilast 
binding to Sudlow’s site I of HSA. Ibuprofen and bilirubin have been included as negative 




5.4.4 Roflumilast nanoparticle manufacture 
Roflumilast-loaded albumin nanoparticles were prepared using method II (Chapter 3) or 
the in-situ loading method for albumin nanoparticle production. Roflumilast was dissolved 
in ethanol and added to stirred albumin solution during the precipitation step of 
nanoparticle manufacture. The reason this method was employed as opposed to method I 
(chapter 3) is because it was hypothesised drug encapsulation would be greater than that 
shown previously in solubilisation studies (2.6 µg per mg albumin). The encapsulation 
efficiency (%) was 41% (Figure 5.5) which corresponds to 4.0 µg/mg albumin. Almost the 
same amount of drug was washed off the particles during the purification process (43.5%) 
with a residual 12.4% drug quantified in remaining glassware etc. The total mass balance 




Figure 5.5 Roflumilast encapsulation efficiency (%). Roflumilast encapsulation efficiency is 
compared to drug recovered from the wash buffer and any residual drug left in glassware. 
 
Nanoparticle size and zeta potential measurements were equivalent in nanoparticles with 
and without roflumilast encapsulated (Table 5.3). All nanoparticle suspension yields were 
100%. Visually, roflumilast-loaded albumin nanoparticles looked similar to control 
nanoparticles (Figure 5.6). 
 
Table 5.3 Size and zeta potential of roflumilast-loaded albumin nanoparticle suspensions 
and "blank" unloaded nanoparticles. Values reported are the mean and standard of n = 3 
nanoparticle batches. 
 
Formulation Size (nm)  Zeta potential 
(mV) 
Roflumilast 124 ± 10  -29 ± 1 





Figure 5.6 Control human serum albumin nanoparticles (left) and roflumilast-loaded 




Storage stability of roflumilast-loaded albumin nanoparticle suspensions was assessed by 
measuring the size and polydispersity index of the suspensions at different time points 
after storage at 4°C and 25°C (Figure 5.7). Colloidal stability of the nanoparticle 
suspensions was maintained for up to six months at 4°C and up to one month at 25°C, after 
which visible signs of aggregation were present. No significant differences were observed 





Figure 5.7 Influence of storage time at 4°C and 25°C on particle size and polydispersity of roflumilast-loaded human serum albumin nanoparticles. The bars 
depict the hydrodynamic diameter (nm, left side axis) of particles and the lines depict the polydispersity index (PDI, right-side axis). Error bars represent 
the standard deviation of 3 measurements. An asterisk (*, or **, or ***) depicts a statistically significant difference in particle size compared to the initial 





5.4.6 Spray-dried roflumilast-albumin powders 
For spray-drying studies, scaling-up of roflumilast-loaded albumin nanoparticle 
suspensions was attempted. Mannitol was selected as the spray-drying excipient (as per 
the optimised formulation selected from chapter 4). Albumin nanoparticles were to make 
up 40% of the total solids content of the spray-dried formulation. The physico-chemical 
properties of the three batches of roflumilast-loaded albumin nanoparticles prepared for 
spray-drying are shown in Table 5.4 along with roflumilast content. As with the original 
nanoparticle suspensions prior to scaling up, the mean drug loading of the suspensions 
was 4 µg/mg albumin. All nanoparticle batches maintained a 100% yield. No visual 
differences were observed between the larger scaled-up suspensions compared to the 
original suspensions.  
 
Table 5.4 Physico-chemical properties of the three roflumilast-loading albumin 
nanoparticle suspensions used in spray-drying studies. 
Roflumilast-
formulation 
Size (nm) Zeta potential (mV) Drug loading with 
albumin (µg/mg) 
Batch 1 160 -25.6 4.0 
Batch 2 201 -28.2 3.1 
Batch 3 179 -26.6 4.0 
 
 
The three batches of roflumilast-albumin nanoparticles were spray-dried in a mannitol 
matrix using a previously optimised method (chapter 4). The particle size distribution 
(PSD) data is shown in Table 5.5. Data from an albumin nanoparticulate control without 
drug is also included for comparison. No significant differences were found between 




Table 5.5 PSD data for spray-dried powders 
Formulation D10 D50 D90 Yield (%) 
Roflumilast 0.99 2.46 5.6 66.5 
Control 1.03 2.49 6.15 69.0 
 
Prior to spray-drying nanoparticle suspensions were measured for size and PDI. After 
spray-drying, powders were reconstituted in water and the supernatant was removed and 
analysed for the presence of nanoparticles. Nanoparticles were found to be present for all 
3 batches of roflumilast nanoparticles tested. Table 5.6 compares the original size of 
nanoparticles prior to spray drying with the size of nanoparticles found after 
reconstitution of the spray-dried powders. It also compares roflumilast content quantified 
from the spray-dried powders with the original drug content quantified. Sizes of all 
batches of roflumilast-loaded albumin nanoparticles increased after spray-drying, while 
control nanoparticles showed no significant difference in size. The slight increase in 
polydispersity index suggests some aggregation may have occurred, although this was not 
apparent through visual inspection of the nanoparticle suspensions. Drug content was 
found to be slightly lower after spray-drying the nanoparticle suspensions [prior to spray-
drying drug content was found to be 3.9 µg/mg ± 0.3 (roflumilast per mg albumin) whilst 
after spray-drying, drug content was found to be 3.1 µg/mg ± 0.1]. This could be attributed 
to loss of drug during the spray-drying process.  
 
Table 5.6 Size, PDI and drug content evaluation of spray-dried powders compared to 
before spray-drying.  
Formulation Original size 
(nm) and [PDI]  




























Aerosol performance of the powders was assessed via FSI screening for fine particle 
fraction (FPF). The aerosolisation properties of spray-dried roflumilast-loaded albumin 
nanoparticles were comparable to the control with similar FPF values.  
 
Table 5.7 FPF and blister evacuation for spray-dried powders. Values reported are for n = 
3 blisters for n = 1 batches for albumin control, and n = 3 batches for roflumilast-albumin 
nanoparticle formulations. 
Formulation Blister evacuation (%) FPF (%) 
Roflumilast-albumin 99.3 ± 0 30.4 ± 5 
Albumin control 98.2 34.7 
 
 





Figure 5.8 Representative scanning electron micrographs (SEM) of spray-dried mannitol 







5.4.7 Roflumilast release studies 
Roflumilast release profiles were assessed over a period of 48 hours with and without the 
presence of trypsin (Figure 5.9). Roflumilast release was less than 20% at 48 h without the 
presence of trypsin (Table 5.8). The presence of trypsin caused a rapid release of drug for 
both nanoparticle and spray-dried systems for the first four hours of incubation, followed 
by a slower release rate for the remainder of the experimental period. At 48 h ~80% of 
roflumilast was released into the receiving medium for both nanoparticle suspensions and 
spray-dried powders. No significant differences were found between the two formulations 
at any time point for both systems with and without protease. Similarity factors (f2) were 
> 50 for both trypsin and non-trypsin systems which indicated that spray-drying has no 
significant influence on drug release rate. Dissolution modelling showed roflumilast 
release for both formulations (nanoparticle suspensions vs. spray-dried powders) in the 
presence of trypsin followed Weibull model kinetics (R2 = 0.9883 and 0.9891, 
respectively). Roflumilast release for the two formulations without trypsin also followed 
Weibull release kinetics with R2 = 0.9984 and 0.9975, respectively. The Weibull model is 
only descriptive and not deduced from any physical law (Costa & Lobo 2001).  
 
Table 5.8 Comparison of cumulative percentage and mass of roflumilast released from 
HSA nanoparticles and spray-dried powders over 48 h, both in the presence and absence 
of trypsin. Data represent the mean and standard of n = 3 experiments. 
Trypsin (-) Trypsin (+) 


















































Figure 5.9 Cumulative roflumilast release from HSA nanoparticles and spray-dried powder 
with and without the addition of 0.1 mg/mL trypsin over 24 h at 37°C. Data represent the 
mean and standard deviation of n = 3 experiments. 
 
5.4.8 PreciseInhale® 
PreciseInhale® is a tool developed by Inhalation Sciences used to generate data on aerosol 
dosing. Customisation of the settings (i.e. tidal volume, breathing rate and route of 
administration) allows the generation of aerosol data for various models, such as guinea 
pigs, rats and the human lung model. In this work, the PreciseInhale® was used to carry 
out a full deposition study on the spray-dried powders generated- similar to a Next 
Generation Impactor (NGI) study but the dose is spread as it would in a pharmacokinetic 
study. Spray-dried powders were first assessed for deposition in stages 1-8 and end filter 
by Marple Cascade Impactor (Figure 5.10). Three systems were tested: 100% mannitol 
spray-dried powder, a blank albumin nanoparticulate system in a mannitol matrix, and 
finally roflumilast-loaded albumin nanoparticles in a mannitol matrix. This was to assess 
the effect (if any) of incorporating nanoparticles and a model drug into the spray-dried 
formulation. The mannitol formulation was found to have highest deposition in stage 6 
(33.1%) followed by stage 5 (17.0%) and blank albumin nanoparticle and roflumilast-
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loaded nanoparticle formulations had highest deposition in stage 5 (27.7% and 31.7% 
respectively). Powder deposition at stage 5 for blank albumin nanoparticles and 
roflumilast were found to be statistically higher than the mannitol spray-dried powder (p 
< 0.05, one way ANOVA, post Holm-Sidak test). No other statistically significant differences 
were noted for deposition profiles of the powders.  
 
The theoretical composition deposition fraction of the particles and the fractional 
distribution between the bronchi and alveoli was calculated for the three powder 
formulations (Table 5.9). No sigificant differences were found in the deposition 
distribution patterns between the three powders tested, however the incorporation of 
nanoparticles in the spray-dried formulation caused a very slight increase in total 
deposition fraction (35% and 36% for blank and roflumilast-loaded nanoparticles 
respectively, compared to 33% for mannitol powder). All powders demonstrated roughly 
1:1 deposition for the bronchi and alveoli i.e. of the inhaled fraction, half would target the 





Figure 5.10 Percentage of powder deposited in different stages of the Marple Cascade 
Impactor for spray-dried powders containing a) 100% mannitol, b) blank albumin 
nanoparticles in a mannitol matrix and c) roflumilast-loaded albumin nanoparticles in a 
mannitol matrix. Data represent the mean and standard deviation of n = 3 replicates. 
 
 
Table 5.9 Total deposition fraction and fractional deposition in bronchi and alveoli as 
determined by PreciseInhale experiments for spray-dried formulations a) 100% mannitol 
b) blank albumin nanoparticles in a mannitol matrix and c) roflumilast-loaded albumin 
nanoparticles in a mannitol matrix. Data represent the mean and standard deviation of n = 
3 experiments. 
Powder Formulation 















35 ± 0.1 49 ± 0 51 ± 0 
Mannitol 
 






It was previously demonstrated in Chapter 4 that albumin nanoparticles could be spray-
dried in a mannitol matrix. To gain understanding of the clinical application of this drug 
delivery platform, the inclusion of an API is necessary. It is important to note the effects of 
the API on the physical characteristics of the formulation itself, as well as how the 
formulation behaves in biologically relevant models. Therefore, in this chapter the effect of 
the incorporation of a model drug with the albumin nanoparticles in the spray-dried 
powder formulation was investigated.  
 
It is difficult to compare the release profile of roflumilast from these studies with the 
literature, as roflumilast and albumin nanoparticulate systems have not been investigated 
previously. However there have been similar drug release studies with different APIs from 
albumin nanoparticles and they all vary in their findings. Das et al. report a drug release of 
90% after 72 hours from aspirin loaded nanoparticles under physiological conditions (Das 
et al. 2005) and Merodio et al. found that 60% of the initially loaded drug was release from 
their most efficient nanoparticle after 5 days of incubation (Merodio et al. 2000). In 
contrast, Lin et al. 2001 only found a release of less than 18% from their surface-modified 
albumin nanoparticles after 8h under physiological conditions. The drug release from 
those nanoparticles was increased to >90% in the presence of trypsin (Lin et al. 2001). 
Interestingly, trypsin did not show an effect on the release profile in the experiments of 
Merodio et al. (Merodio et al. 2000). This is in line with the seemingly recurring findings in 
this work where trypsin appears to greatly assist in the release of drug from the particles. 
Even without the addition of trypsin, up to 19% roflumilast was detected in the receptor 
medium. This could be indicative of some drug particle release from the nanoparticles 
having been loosely attached to their surface, while the trypsin broke down the albumin 
nanoparticles and released drug contained within them. This combination of different 




The key finding from the drug release studies in this work is that the formulation of the 
nanoparticles in dry powder form had no effect on the release profiles of roflumilast- as 
hypothesised with the selection of mannitol as the excipient due to its excellent aqueous 
solubility. Kinetics modelling showed roflumilast release for all systems tested followed 
Weibull release kinetics. Weibull release is modelled by Equation 5.1, where m is the 
accumulated fraction of drug in time t, a is the time scale of the process and Tt represents 
the lag time before the onset of the drug release process which is usually zero. The shape 
parameter is b which characterises the curve as either exponential (b = 1), s-shaped with 
upward curvature (b > 1) or parabolic with a higher initial slope and then following the 
exponential (Costa & Lobo 2001). The Weibull model is only empirical and does not have 
any kinetic element- it can only describe the release kinetics of the drug but not 
adequately characterise it and therefore its uses are limited (Costa & Lobo 2001).  
 
Equation 5.1 
        





It is unclear why spray-drying seemed to cause drug loss. Roflumilast retention caused by 
high inlet temperature could be a possible explanation for this (Broadhead et al. 1992). 
SEM micrographs show spherical particles for both formulations with and without 
nanoparticles, with nanoparticle-containing formulations appearing to have a slight 
rougher surface. Powders containing roflumilast showed some bumps on the surface of 
the spherical particles. Further particle surface analysis would need to be carried out in 
order to assess whether this is an effect of the drug itself. This could be carried out using 
fluorescent labelling techniques [e.g. confocal laser scanning microscopy (Sham et al. 
2004)]. Raman microscopy can provide structural information on a molecular level and 
would be able to distinguish between roflumilast and the mannitol matrix and albumin. 
Scanning electron microscopy with energy-dispersive X-ray analysis (SEM-EDX) may also 
work. This technique works by quantitative and qualitative analysis of each element in the 
140 
 
sample and as roflumilast contains fluorine and chlorine it would be easily distinguishable 
from the mannitol matrix and albumin. However, the small amount of drug present in the 
sample may be difficult to detect.  
 
Dose/deposition modelling experiments with the PreciseInhale® found that the average 
deposition fraction for spray-dried powders containing roflumilast nanoparticles was 
36%. This is also similar to the FPF calculated from FSI experiments (30%). This means 
the administration (aerosol delivery via inhalation) of a single capsule containing 10mg of 
powder would result in a roflumilast dose of roughly 6 µg. The advantages of direct 
pulmonary targeting have been touched upon earlier. Direct aerosol delivery enables 
efficacy of a drug to be achieved at a fraction of the oral dose, e.g. 200-800 μg vs 4-16 mg 
for salbutamol in humans (>200-fold decrease in dosage) and pre-clinical efficacy has 
been reported with 33-fold lower doses of inhaled rifampicin compared to oral dosing in 
preclinical studies (Pandey et al. 2003). This data gives a good indication for dose 
estimation in preparation for pharmacokinetic studies. Opportunities to deliver even 
higher doses to the lungs could occur with multiple dosing or larger dosing devices 
(carrying > 10mg powder per dose) or even further optimisation of the nanoparticle 
formulation to allow a higher roflumilast to albumin ratio, thereby increasing the overall 
drug content. As the oral dose of roflumilast in tablet form is 250 micrograms daily, the 
predicted dose values calculated here appear promising for achieving a therapeutic effect, 
however this would need to be assessed with preclinical pharmacodynamic studies to 






In summary, the work in this chapter has culminated in the development of a formulation 
for pre-clinical evaluation. It could be shown from this work that the incorporation of a 
model drug with the developed dry powder formulation was possible, with good drug 
recovery from the spray-drying process and little effect on the aerodynamic properties of 
the powders produced. Roflumilast-albumin interactions were studied, roflumilast-loaded 
albumin nanoparticles were successfully manufactured and spray-dried using the 
optimised formulation from Chapter 4. Roflumilast was released from the spray-dried 
microcarriers in very much the same manner as they did in suspension form, showing the 
mannitol matrix in which they are formulated does not hinder drug release. Finally, 
deposition modelling using the PreciseInhale® system showed promise for the clinical 





Chapter 6 General discussion 
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This chapter will recap the general advantages and state of the art in regard to inhaled 
nanomedicines, followed by a review of the specific aims of this thesis and how these were 
addressed by the development of albumin-based formulations (albumin solution and 
albumin nanoparticle-based formulations) for the delivery of hydrophobic model anti-
tuberculosis drugs (BTZs) as well as the development of respirable microparticles 
containing albumin nanoparticles for the delivery of another model hydrophobic drug 
compound (roflumilast). 
 
Delivery to the lungs provides an attractive route of drug administration for several 
reasons. As well as offering a non-invasive route for drugs normally delivered by injection, 
there is potential for achieving an improved pharmacokinetic profile, the prospect of 
reduced systemic side effects, use of lower doses and direct targeting for pulmonary 
diseases (Newman 2017). Unfortunately, there are some challenges with using the 
pulmonary route of drug delivery including the short duration of action of therapeutic 
agents (possibly due to the high permeability rate of the drug), the natural defence 
mechanisms of the lung designed to remove inhaled materials as well as difficulties in the 
presentation of drugs in respirable formulations. Hydrophobic APIs often present more 
difficulties than their hydrophilic counterparts when it comes to the design of an inhalable 
formulation in terms of stability, lung targeting and efficacy.  
 
Nanoparticles offer the opportunity to assist with the delivery of hydrophobic drug 
compounds by increasing their solubility. They also offer the advantage of sustained drug 
release, thereby reducing dosing frequency (Sung et al. 2007). In terms of the treatment of 
respiratory diseases, nanoparticles have the potential to increase and sustain drug levels 
locally in the lung i.e. the site of the disease. This local targeting of disease is beneficial, 
particularly in combination with the potential of nanoparticles to protect APIs from 
degradation until they reach their target. Furthermore, their small size is thought to help 




Historically, there have been safety concerns regarding inhalation of nanoparticles. It has 
been reported that long term exposure to nanoparticles may cause serious damage to 
health such as pulmonary fibrosis, granulomas, hypoxaemia and pleural effusion (Bakand 
et al. 2012; Song et al. 2009; Oberdörster et al. 2005). It has also been found that that 
inhaled nanoparticles may pass into the systemic circulation and accumulate in secondary 
organs such as the brain and organs of the digestive system (Balasubramanian et al. 2013; 
Geiser & Kreyling 2010). Several possible mechanisms of nanoparticle toxicity have been 
suggested, ranging from immediate reactions to long term effects (Bakand et al. 2012). 
Nanoparticles can penetrate cell membranes, enter different compartments of the cell and 
be a direct cause of cell injury owing to their small size (Song et al. 2009; Gojova et al. 
2007). The complex mechanisms of nanotoxicity make it hugely important to gain a better 
understanding of the fate of nanoparticles in the lungs including their biological 
interactions and potential nanotoxicity before they may be considered as clinically 
acceptable for pulmonary drug delivery purposes.  This means that as well as being 
retained in the lung for the duration required in order to deliver the therapeutic payload, 
it has to be demonstrated that particles (and degradation products) are also effectively 
cleared from the lungs and have no or little associated toxicity i.e. show that they are 
biodegradable and biocompatible.  
 
There are technical challenges associated with the development of nanoformulations for 
delivery to the lungs. This includes a reproducible manufacturing method in which the API 
must be compatible with the excipients and manufacturing conditions. Nanoparticles must 
have the ability to interact with APIs to achieve adequate drug loading but release drug 
upon delivery of the nanoformulation to exert its therapeutic effect. This may prove to be 
difficult with particularly hydrophobic APIs. Stability of nanoparticle-based formulations 
can be an issue owing to their small size and high surface area which can lead to particle 
agglomeration. The development of a larger microparticle-containing nanoparticles can 
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improve the stability of the formulation as well as making it easier to deliver the 
nanoparticles to the lung (as smaller particles would just be exhaled back out again). The 
formulation must also be safe and effective at delivering therapeutic agents to the lung via 
inhalation.  
 
The aim of this work therefore was to study the potential of albumin nanoparticles as drug 
carriers for delivery to the lung, with a focus on hydrophobic drug compounds. This 
included the development of respirable microparticles containing drug-loaded albumin 
nanoparticles for delivery to the lung by inhalation.  Although albumin nanoparticles have 
been studied previously (Elzoghby et al. 2012), this study investigated how nanoparticle-
albumin interactions affected drug-loading using different methods of manufacture and 
the stability of the nanoparticles on storage/release of drug after administration.  There is 
a paradox with many nanomedicines that achieving high loading of a drug with affinity for 
the nanoparticle may be detrimental to the liberation of the drug after administration.  
The hypothesis tested for albumin nanoparticles was that proteases in the lungs will 
enzymatically break down the particles after administration which will release drug and 
prevent particle accumulation.  Not only was this tested by measuring drug release using 
model fluids to represent lung protease concentrations, the effectiveness of anti-
tuberculosis drugs when delivered in the particle formulation was investigated using an 
infected macrophage model. 
 
In this thesis, albumin nanoparticles were generated initially from bovine serum albumin 
(BSA) using a previously reported modified desolvation technique (Weber, Kreuter, et al. 
2000). This work was then translated to human serum albumin (HSA) (Chapter 2) to 
verify the findings using pharmaceutical grade material that has been used previously in 
medicinal products. No differences were found between nanoparticles manufactured with 
BSA and HSA. HSA was subsequently employed for all the following work. The physical 
characteristics of the nanoparticle suspensions (size, zeta potential) were carried out in 
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different conditions to explore the robustness of the measurement technique (DLS) and 
the reproducibility of the nanoparticle manufacturing method. Nanoparticles were formed 
with sizes between 100-200 nm, with low polydispersity and zeta potential (when 
measured in neutral medium i.e. water) of ~-25 mV, and when measured in saline, the zeta 
potential increased to ~-10mV due to shielding effect. This was found to be similar to the 
properties of previously manufactured albumin nanoparticles using the similar 
desolvation method (Zhao et al. 2010; Langer et al. 2003). The suspending medium had no 
effect on the size characterisation of nanoparticle suspensions. 
 
Both BSA and HSA nanoparticle suspensions were found to have similar stability. Both 
were physically stable for up to one month at 25°C while up to six months stability was 
observed for nanoparticle suspensions stored at 4°C. This was consistent with preliminary 
studies and previously reported studies with BSA (Woods et al. 2015). Using a simple 
protease-digestion model to look at the breakdown of albumin nanoparticles, albumin 
nanoparticles were found to be stable in PBS without the presence of a protease enzyme, 
whereas in the presence of enzyme at concentrations similar to those found in the lung 
lining fluid, there was an initial fast rate of particle breakdown followed by a slower phase. 
TEM imaging confirmed the digestion of albumin nanoparticles. This data was promising 
in terms of the application of albumin nanoparticles as a controlled release formulation as 
it showed they are likely to be retained in the lungs for a timeframe sufficient to have a 
therapeutic effect but are subject to enzymatic degradation which alleviates concerns 
about their elimination from the body.  
 
The loading of drug compounds in albumin nanoparticles has been carried out previously. 
However these studies have mostly used well-established drugs that are “easier” to 
formulate as they have favourable solubility e.g. aspirin and ganciclovir (Das et al. 2005; 
Merodio et al. 2000). As well as providing a controlled release platform for drug delivery 
to the lung, albumin nanoparticles were investigated as a carrier for very poorly soluble 
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drug compounds that have or would have poor bioavailability if formulated as a 
conventional oral formulation (e.g. tablets). In Chapter 3, benzothiazinones were used as 
model compounds for this purpose. It is important to understand how drugs interact with 
albumin and so BTZ-albumin interactions were studied in this chapter. Interesting insights 
into binding with Sudlow’s binding site I on the albumin molecule were noted, namely the 
relationship between the binding and release of BTZ compounds, with the more 
hydrophobic FG 2 demonstrating stronger binding and lower drug release compared to 
the less hydrophobic IR 20. Despite Sudlow’s site (or drug binding site I) being the most 
important for hydrophobic molecules (Ghuman et al. 2005), it is also important to note 
there are other binding sites on the albumin molecule which were not characterised in this 
work, namely drug binding site 2. Due to time constraints the affinity of tested compounds 
for drug binding site 2 was not explored. Since this site is known to largely bind polar 
molecules it was not considered as necessary for this work, however it would be 
interesting to compare binding sites and drug-albumin interactions more fully.  Not least, 
it would be interesting to understand how binding alters as the particles degrade and 
albumin or albumin fragments and drug are released. 
 
Drug loading was optimised by adopting slight differences in the manufacturing method of 
the nanoparticles. From the drug loading assessment, it became apparent that delivery in 
albumin nanoparticles is suitable only for drugs with high potency (i.e. activity in the 
micromolar range). For less potent compounds, the amount of albumin that would need to 
be delivered would be larger, and the effects of this excipient burden on delivery by 
inhalation and toxicity. would need to be explored. Although the loading and losses of drug 
were mapped during the nanoparticle manufacture process to optimise the method, in 
order for the drug to exert a therapeutic effect, it must be able to be released from the 
nanoparticles. Therefore, drug release experiments were carried out in release buffer 
characteristic of the lung lining fluid. A reassuring finding from these experiments were 
that the formulations were very stable in aqueous suspension without protease, indicating 
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good stability of the nanoparticles. However, upon the addition of trypsin a rapid release 
of drug was observed. An advantage of albumin nanoparticle systems compared to 
nanoparticles made from other materials (e.g. synthetic polymers, lipids) is that despite 
the change in albumin structure when in nanoparticle form, enzymatic clearance 
mechanism for endogenous albumin also play a role in their clearance, alleviating 
concerns about accumulation. 
 
It was expected that the drug-loaded human serum albumin nanoparticles would be 
retained in the lungs when delivered in vivo with clearance patterns similar to the 
observations from previous studies with blank (unloaded) BSA nanoparticles. An in vivo 
biodistribution and clearance study comparing BSA nanoparticles with BSA solution 
showed that albumin delivered in nanoparticles was retained longer in the mouse lung 
compared to albumin solution and was distributed more highly into macrophages and 
lung tissue (Woods et al. 2015) . The time-frames observed fit the findings for nanoparticle 
degradation from experiments in this thesis. When BTZ-loaded albumin nanoparticles 
were evaluated in the in vitro infected macrophage model, the drug delivered by carrier 
was equally or more effective than when delivered unbound.  This suggests that not only 
may the drug be retained in the lungs for longer, it may be delivered into cells more 
effectively where it can be released to affect the enhanced chemotherapeutic effect. 
 
Formulation into larger microparticles containing albumin nanoparticles was conceived as 
the necessary next step for developing albumin nanoparticles for inhalation. The small size 
of the nanoparticles makes them prone to aggregation and if delivered in their primary 
particle size it means it is likely they would be exhaled back out again following inhalation, 
hence formulation as part of a larger microparticle would provide a respirable powder 
with the prospect of high lung deposition.  It was hypothesised that spray drying would 
provide a particle engineering method to embed the nanoparticles in a readily-soluble 
matrix that would form respirable microparticles that would dissolve rapidly on contact 
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with aqueous medium and release the nanoparticles without any impairment of their form 
or functionality.   
 
Heuristic developmental studies with spray-drying confirmed the exceptional robustness 
of the albumin nanoparticles as they were recoverable without any change to their 
original properties after the spray-drying process. It was anticipated that albumin as a 
protein may not be able to withstand the inlet and outlet temperatures of the spray drier; 
however, this was not the case. BSA-apiginen conjugates produced by a different 
technology where homogenisation is employed to produce such conjugates, were spray-
dried in a study by Papay et al. (Pápay et al. 2017). Similar outlet temperatures were used 
in this study, with no adverse effects observed for the albumin formulation, however one 
should be wary about comparing these findings with the albumin systems spray-dried in 
this thesis as differences in Papay’s include: i) albumin is utilised as a stabiliser with the 
drug to form conjugates, rather than active loading of drug into nanoparticles formed of 
albumin, ii) the study use of BSA rather than HSA iii) different excipients were used. A 
major difference found in the spray-dried powders produced by Papay et al. compared to 
the ones produced in this thesis is the drug release. Even without enzymes in the release 
buffer up to 80% of drug was released from the formulation. It appears the albumin played 
little or no part in modulating the release of the drug and its role in the formulation was to 
facilitate the spray-drying process to produce a respirable powder. The drug-loaded 
albumin nanoparticles synthesised and studied in this thesis control the release of drug 
over a longer time period and are stable without the presence of enzyme. 
 
Following the approach of using pharmaceutically-acceptable materials, it was decided to 
utilise commonly used spray-drying excipients that fall under the category of “generally 
regarded as safe” excipients or gras excipients. Another consideration with regard to 
translation to the clinic was the importance of optimising for albumin nanoparticle 
content in order to achieve maximise the drug: excipient ratio and deliver the highest 
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payload possible of drug-loaded nanoparticles without adversely affecting the 
aerodynamic properties of the powder (chapter 4).   
 
Interestingly, switching from BTZ to a new drug for further formulation studies proved 
unproblematic suggesting that for certain classes of API, the albumin nanoparticle may 
provide a platform technology. In terms of roflumilast-albumin interactions, roflumilast 
behaved in a similar way to the BTZ compounds (chapter 3) in its degree of binding to 
drug binding site I on the albumin molecule, and degree of solubilisation by albumin. 
However, there were differences in the drug release characteristics of both spray-dried 
and non-dried roflumilast nanoparticle systems compared to the BTZ release 
characteristics from chapter 3. BTZ release from albumin nanoparticles was very low in 
the absence of trypsin (<5%) however for the roflumilast-albumin formulations, drug was 
released to the extent of almost 20% after 48 h in aqueous suspension, even in the absence 
of protease. This suggests different mechanisms of binding of roflumilast to the albumin 
nanoparticles. Drug may attach loosely to the surface of the albumin nanoparticles, and it 
may be these loose interactions that cause drug release even without the breakdown of 
the nanoparticles with protease. The roflumilast-loaded albumin nanoparticles may 
contain more of these loose interactions compared to the BTZ-loaded albumin 
nanoparticles. Drug may also bind tightly within the core of the albumin nanoparticles 
upon manufacture, and these drug molecules may only be released after the digestion of 
the albumin nanoparticles with trypsin. It was encouraging to see the mannitol matrix of 
the spray-dried powder formulations had no effect on the release behaviour of roflumilast 
from the albumin nanoparticles as it was important for the albumin nanoparticles 
themselves to dictate the release of the drug.  
 
The main findings of this work have been to advance the understanding of how to design 
and formulate albumin nanoparticle-based formulations for potential application in 
inhaled drug delivery. The robustness and ease of scale up of the manufacturing method, 
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versatility of albumin-drug interactions and finally the development of respirable 
microparticles containing albumin nanoparticles are among the key features of this work.  
The demonstration that delivery of BTZ using nanoparticles can enhance 
chemotherapeutic activity provides encouragement to develop further albumin NP 
formulation to test the effect on pharmacokinetics and pharmacodynamics in vivo.  
 
Future work 
As a follow-up to the aerosol testing carried out on the spray-dried powders containing 
roflumilast-loaded albumin nanoparticles, further quantitative analysis of the drug in a 
next generation impactor (NGI) study would be useful to evaluate the aerodynamic 
particle size distribution and provide an estimate of the fate of the likely regional 
deposition of drug in the lungs after aerosol delivery. The in vivo behaviour of the 
microparticle systems developed in this thesis needs to be investigated to augment the 
understanding of the clearance and biodistribution of the microparticles and their payload 
of nanoparticles and API.  This could be coupled with imaging studies by labelling the 
albumin nanoparticles. In one study albumin nanoparticles were labelled with fluorescein 
isothiocyanate (Roser et al. 1998).  Further physical assessment of the powders may also 
be useful, such as x-ray powder diffraction, differential scanning colorimetry (DSC), as well 
as the use of techniques to look at the distribution of nanoparticles within the 
microparticle matrix and at the surface. 
 
Other excipients matrices could be investigated, this work evaluated trehalose/leucine, 
but focused on mannitol, however there are other “generally regarded as safe” excipients 
that could be explored, such as l-alanine (Razavi Rohani et al. 2014). Only dry powders 
were explored in this work as formulation options for the albumin nanoparticles. Despite 
previous studies investigating nebulised aerosols containing polymeric nanoparticle 
dispersions (Dailey et al. 2003; Yang, Tam, et al. 2008; Beck-Broichsitter et al. 2012), there 
are no studies looking at the delivery of albumin nanoparticle suspensions to the lung 
152 
 
through nebulisation, therefore nebulisation should also be explored for manufacturing 
and scale-up feasibility, stability and effectiveness.  
 
Despite the BTZs being model drugs for the purpose of this thesis, the novel BTZ 
compounds are of great interest for tuberculosis treatment (Makarov et al. 2014; Trefzer 
et al. 2012; Batt et al. 2012). The infected macrophage model provides a good first step for 
investigating the potential benefits of an albumin nanoparticle carrier for the BTZ 
compounds. However, it would be a key finding to evaluate the activity of the BTZ-albumin 
systems in vivo to test whether the encouraging findings in vitro can be reproduced after 
pulmonary delivery in a pre-clinical model of tuberculosis. 
 
As this work looked at demonstrating the potential of albumin nanoparticles as a 
hydrophobic drug carrier, it would be useful to assess how other similar drugs behave in 
these systems. The typical drug that may be of use to pursue would be hydrophobic and 
have relatively high potency i.e. drugs that would benefit from an improved solubility 
offered by albumin nanoparticles, or that otherwise have poor bioavailability as an oral 
formulation. Medicines that only exist as injectable formulations may benefit from a less 
invasive route of administration, such as pain relief medication or protein-based biologics 
such as monoclonal antibodies. Other anti-infective drugs for respiratory infections may 
also be suitable candidates for this albumin nanoparticle-based delivery platform if the 
enhanced lung exposure leads to greater efficacy and reduces the dose to a realistic 
inhaled dose. Inhaled tobramycin exists as a product in the treatment of cystic fibrosis, 
other antibiotics are nebulised “off-label” in the treatment of cystic fibrosis, however more 
work needs to focus on developing inhaled antibiotics for other respiratory conditions 





It would be useful to assess the activity of the roflumilast-loaded albumin nanoparticle 
containing microparticles in an appropriate disease model. The bronchodilator and anti-
inflammatory properties of roflumilast have been investigated previously in rats and 
guinea pigs (Bundschuh et al. 2001). Roflumilast is a drug that would benefit from a 
delivery system that improves lung selectivity in order to avoid systemic side effects.  The 
formulation developed provides an opportunity to measure 
pharmacokinetic/pharmacodynamic relationships and use these to inform the design and 
development of the drug carrier system. Although a few studies have looked at the safety 
profile of albumin nanoparticles, this requires further investigation. Being an endogenous 
molecule makes albumin attractive for drug delivery purposes as does its inert nature.  
The toxicity and safety of the albumin nanoparticles and microcarrier systems needs to be 
assessed in acute and longer-term studies and an evaluation is needed regarding the 
potential for introducing immunogenicity as a result of the formulation steps, e.g. cross 
linking and aggregation of partially degraded particles. Histopathological examination of a 
range of organs following inhalation can be used to evaluate systemic toxicity, as well as 
careful histopathological evaluation of the respiratory tract as it is the site of most of the 
deposition of the inhaled dose (Wolff 2015).  
 
Conclusion 
The work in this thesis has demonstrated that albumin nanoparticles manufactured by a 
modified version of a well-documented method can be loaded with very hydrophobic 
drugs, release them in a therapeutically relevant timeframe and provide an enhanced 
chemotherapeutic effect in a relevant in vitro disease model. The albumin nanoparticles 
were formulated as respirable microparticles within a mannitol matrix with good 
respirable properties. The formulation was developed to deliver roflumilast - a drug with 
therapeutic relevance for pulmonary inflammation. Dose deposition studies using the 
PreciseInhale® modelling system showed good potential bronchial/alveolar deposition 
for the powders. In conclusion, this work has shown the potential of albumin 
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nanoparticles as a carrier for poorly soluble drugs, as a carrier with controlled release 
properties, and finally as the key component of an inhalable microcarrier formulation for 
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